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 ABSTRACT 
Secondary lymphedema is a common complication after surgical treatment, particularly 
after breast surgery, in which very little is understood about possible determinants. Multiple 
studies have been conducted to identify specific genes contributing to inherited primary 
lymphedema. Some of these causative genetic factors may also play a role in the development of 
secondary lymphedema.  Among them, the GJC2 and MET genes have been identified as being 
associated with primary lymphedema. Further investigation using common SNP analysis of the 
GJC2 and MET genes was performed in patients post breast surgery, with and without secondary 
lymphedema to determine whether variants of either gene could be a determining factor for 
developing secondary lymphedema after surgical treatment. Survey data analysis addressing 
various psychosocial and bio-behavioral factors was also analyzed to indicate whether these 
candidate genes affect chronic pain and psychosocial traits in patients with secondary 
lymphedema compared to matched controls. Variants at rs11800309 of the GJC2 gene and 
patients’ Pain Catastrophizing Scores were significant (ά=.1) for predicting lymphedema. 
Variants of rs41737 of the MET gene was observed to have an effect on brief pain inventory, 
perceived stress scores, and depression scores. Variants at rs7539762 and rs11800309 of the 
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GJC2 gene were observed to effect anxiety levels. Age was observed to be inversely related to 
all psychosocial phenotype scores. This current study has public health significance because it 
can help identify women who may be at an increased risk for developing secondary lymphedema 
after breast surgery. 
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1.0  INTRODUCTION 
Lymphedema is a condition in which lymph is unable to flow through the lymphatic vessels. 
This condition causes multiple physical and psychological symptoms for individuals that are 
affected. Physical symptoms of lymphedema include swelling of the limbs, restricted range of 
motion, discomfort and pain, fibrosis, and the possibility of recurrent infections. This condition 
may also have psychosocial effects on an affected individual. These psychosocial effects may 
include depression, anxiety, sleep disturbances, cosmetic concerns, lower self-esteem, and 
overall reduced quality of life.  
There are two different types of lymphedema; primary lymphedema and secondary 
lymphedema (Mohler ER, et al). Although primary and secondary lymphedema have the same 
set of symptoms, the causes of both conditions are very different. Primary lymphedema is an 
inherited condition in which the lymphatic vessels of the body fail to develop or function 
properly. There are multiple genes that have been identified in which mutations can cause 
lymphedema. Primary lymphedema has varying ages of onset. Symptoms can occur soon after 
birth and have also been seen to develop early in childhood (Smeltzer et al., 1985).  Secondary 
lymphedema is acquired due to damage to the lymphatic system which prevents lymph from 
flowing through the vessels. Secondary lymphedema may be caused from trauma, infection, 
radiation, or surgery. However, not all individuals who experience these triggers develop 
lymphedema. There is no current cure for lymphedema (Mohler ER, et al). 
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The main goal of this current study is to use genotyping technology to determine if 
common variants within two genes, GJC2 and MET which are identified to cause primary 
lymphedema, cause a predisposition for secondary lymphedema development in a patient post-
breast surgery. This current study also aims to analyze the association of common variants in 
GJC2 and MET with chronic pain and psychological phenotypes. 
1.1 AIMS 
Aim 1: To measure participants’ experience with chronic pain, perceived stress, sleep 
disturbance, depression, and anxiety after breast surgery by means of a telephone survey.  
Aim 2: To genotype common Single Nucleotide Polymorphisms (SNPs) in GJC2 and MET: 
Three common tagging SNPs in GJC2 (rs7539762, rs7523917 and rs11800309) and two 
common tagging SNPs in MET (rs41737 and rs13223756) were selected based on reported minor 
allele frequencies.  
Aim 3: To analyze the association of GJC2 and MET common variation with secondary 
lymphedema, chronic pain and psychosocial variables.  
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1.2 BACKGROUND AND SIGNIFICANCE 
1.2.1 The Lymphatic system and Lymphedema 
The lymphatic system has many important functions, however it remains quite understudied 
compared to other body systems. The lymphatic system interacts with many different body 
systems.  The lymphatic system removes interstitial fluid from body tissues and helps with the 
transportation of white blood cells to the lymph nodes and bones, providing fluid balance. The 
lymphatic system also interacts with the villi to assist the digestive system in the absorption and 
transportation of fatty acids.  Another vital function of the lymphatic system is to transport 
antigen presenting cells to the lymph nodes in order to stimulate an immune response (Freeman, 
S, 2008).   
 Due to the high pressure of the circulatory system and the fact that capillaries are thin, 
fluid is able to leak from the capillaries into surrounding space. This fluid is called interstitial 
fluid because it is found between the cells of the body. The majority of interstitial fluid is able to 
diffuse back into the capillaries due to the osmotic differences of the fluid. The concentration 
difference exists because large proteins are retained in the blood capillaries due to their size 
inhibiting them from diffusing out of the capillaries.  The remaining fluid that does not reenter 
the capillaries enters the lymphatic vessels as lymph. Lymph is a mixture of fluid and white 
blood cells which circulates through the lymphatic system.  Only about 2-5 percent of plasma 
volume form lymph each day (Freeman, S, 2008).  
 The lymphatic system consists of lymphatic ducts and lymphatic vessels. Lymphatic 
ducts permeate all tissues in order to provide a channel for the lymph to flow. Lymph does not 
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have a specific organ designated to pump the fluid through the channels. Lymph is able to flow 
through these channels by the contraction of skeletal muscles, the contraction of smooth muscles 
in larger vessels, and thoracic pressure changes from respiration. The lymph can deliver nutrients 
and gases to the tissues. All of the tiny channels eventually combine to form large vessels. 
Lymph is able to reenter the circulatory system by means of the subclavian veins after it is 
filtered by lymph nodes (Sherwood, 2012).  
 The lymphatic system plays a role in the immune system and contributes to the body’s 
protection against virus, bacteria, and cellular debris that can cause infections.  Lymph nodes are 
small organs, consisting of masses of lymph tissue that are located throughout the body. These 
organs are responsible for filtering the lymph fluid and for detecting any possible pathogens. 
Lymph nodes are responsible for modifying lymphocytes to fight infections. Examples of lymph 
nodes include the tonsils located in the throat and Peyer’s patches located in the small intestine 
(Sherwood, 2012).  
 Other specific structures of the lymphatic system also contribute to immune response. 
These structures include the spleen and the thymus gland. The spleen is similar to lymph nodes, 
however rather than filtering lymph fluid, the spleen filters blood. Pathogens that are present in 
the blood generate a response from lymph nodes when the blood passes through the spleen. The 
spleen also functions to filter older, non-working red blood cells from the blood and act as a 
reservoir for oxygen rich blood.  The thymus gland is another important structure of the 
lymphatic system, however the entire function of the thymus gland remains unknown.  The 
thymus gland size decreases as an individual ages.  Before puberty this gland is made up of 
mostly lymphatic tissue. It is understood that the thymus gland provides a location for immature 
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T lymphocytes to be held after leaving the bone marrow. It is in the thymus gland that the 
immature T lymphocytes fully develop. T-lymphocytes that are beneficial to the immune system 
develop, while detrimental T-cells are rejected. This gland also functions to secrete hormones 
that may affect the body’s immunological response. (Sherwood, 2012). 
The lymphatic system plays an important role in the digestive system. A specific lymph 
vessel, lacteals, are located in the villi of the intestines to help with the absorption of fat. The 
liquid that contains the absorbed fat is called chyle. Chyle is also drained into the subclavian vein 
in order to enter the circulation to be transported to tissues.  
Lymphedema is a disorder of the lymphatic system in which a block in lymphatic vessels 
inhibits fluid from flowing through the lymphatic channels. This leads to the progression of 
numerous symptoms. The most common physical features in the early stages of lymphedema is 
noticeable edema, otherwise known as swelling, and restricted movement which is most often 
located in the extremities. Some psychological features include feelings of heaviness in the areas 
of the edema as well has pain. Certain skin changes can also occur because of the edema. These 
skin change may include certain wart-like growths, thickening of the outer layer of the skin 
(hyperkeratosis), and papilloma growth in cases of severe lymphedema. Severe lymphedema 
may lead to significant deformity. A deformity of a particular area can effect function and 
mobility. A deformity may also have psychosocial implications. Body deformity can lead to 
depression, social anxiety, low self-esteem and overall lower quality of life in individuals. 
Increased risk for infections and low auto-immune response are other obvious symptoms of 
lymphedema because the immune system is unable to function properly (Mohler ER, et al).  
5 
Lymphedema may be inherited or acquired. The type of lymphedema that is inherited is 
described as primary lymphedema. Primary lymphedema is less common compared to secondary 
lymphedema. Primary lymphedema has a reported incidence of 1.5 per 100,000 individuals 
under the age of twenty in North America (Smeltzer et al, 1985). Primary lymphedema may be 
inherited in either a dominant or recessive manner, depending on which gene is responsible for 
symptoms. Multiple genes have been identified to cause primary lymphedema and onset of 
symptoms can vary from infancy, to childhood and adolescents, or even adulthood.  
1.2.2 Genetics of Primary Lymphedema 
The University of Pittsburgh Department of Human Genetics conducted a large family study to 
investigate the genetic causes of primary lymphedema. The genes were identified by 
interviewing families in which primary lymphedema was present. Blood samples were obtained 
from patients and their family members, both with and without primary lymphedema. This study 
revealed mutations in seven genes that cause primary lymphedema. These genes include FLT4, 
FOXC2, HGF, MET, SOX18, CCBE1, and GJC2 (Ferrell, R. E., Finegold, D. N., & Levine, K). 
The FLT4 gene is located on chromosome 5 and codes for VEGFR3 (Ferrel et al., 1998). 
This gene is involved in the development of lymphatic vessels during fetal development. The 
FOXC2 gene causes lymphedema-distichiasis syndrome, which causes lymphedema later in life 
(Traboulsi et al, 2002).  SOX18 is a gene on chromosome 20 which is involved in fetal 
development and associated with Hypotrichosis-Lymphedema-Telangiectasia syndrome (Irrthum 
et al., 2002). HGF and MET are located on chromosome 7 and play a role in the growth and 
development of the lymphatic vessels. CCBE1 is also associated with lymphatic development 
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and Hennekam syndrome (Alders et al, 2009). GJC2 is on chromosome 1 and affects the 
function of the lymphatic system rather than the development (Ferrell et al, 2010).  
1.2.2.1 GJC2 
Gap junction protein, gamma 2, 47kDa, GJC2, is a gene that provides the instruction for making 
a gap junction protein. Gap junction proteins are part of the connexin family of proteins, which 
play an essential role in cell-to-cell signaling, response to toxic substances, and transmembrane 
transport (NCBI, 2015). Connexins connect body cells and create channels for small ions, 
substances, and electrical signals to be transported from one cell to another. Connexins also have 
effects on non-connexin protein interactions within a cell flow (Merlijn J et al, 2014).   
Although the relationship between connexins and the lymphatic system is a topic that 
remains understudied, some findings suggest that connexins and gap junction proteins play a 
significant role in the function and development of the lymphatic system. Early electron 
microscopy, immunohistochemistry, and pharmacological inhibitor studies all suggest the 
presence of gap junctions in lymphatic vessels. Functional studies on animal lymphatic systems 
observed that rhythmic contraction causes the lymph fluid to flow through the vessels.  For cells 
to have a synchronized action, gap junction proteins would be essential in order to provide the 
communication and connection between the cells.  Studies that measure the expression level of 
genes also suggest the importance of connexin.  GJC2 has been observed to be expressed in 
lymphatic endothelial cells and not blood endothelial cells. This suggests that GJC2 plays a key 
role in the connection of lymphatic cells. Other evidence that connexins are essential for 
lymphatic system function comes from the observation of mutations. Studies have observed 
mutations in the GJC2 gene in patients who have been diagnosed with primary lymphedema. 
Mutations were identified in the different regions of the gene. This indicates that the GJC2 gene, 
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as well as other connexin and gap-junction proteins, provides assistance with lymphatic flow 
(Merlijn J et al, 2014).  
Finegold et al. (2012) studied GJC2 using biological samples collected at Magee hospital 
and identified four rare variants present in post mastectomy patients with secondary lymphedema 
that were not found in post mastectomy patients without secondary lymphedema symptoms. In 
addition, none of the non-breast cancer control group had these GJC2 variants. This suggests that 
variants in this gene may increase an individual’s risk for developing secondary lymphedema 
after surgical treatment. 
1.2.2.2 MET 
MET proto-oncogene, receptor tyrosine kinase, MET, is a proto-oncogene. Proto-oncogenes help 
control both cellular division and apoptosis. These groups of genes are essential for regulating 
cell life and when mutated, play a role in the development of cancers.  The product of this gene 
is the hepatocyte growth factor receptor and activates the tyrosine kinase signaling cascade. 
Kinases help regulate cell functions. Tyrosine kinase transfers a phosphate group from ATP to 
proteins, which can either initiate or terminate certain functions between cells.  
MET has been identified as a proto-oncogene, and the MET pathway is involved in the 
formation of multiple forms of cancers (Peschard and Park, 2007, Mizuno S. and Nakamura. T, 
2013). As a proto-oncogene, MET functions to regulate cell proliferation, scattering, 
morphogenesis and survival. During early embryonic development this gene regulates 
development and migration of muscles and neuronal precursors, angiogenesis and kidney 
formation. MET endorses differentiation and proliferation of hematopoietic cells which is 
essential in early development. Additionally, this gene contributes to organ regeneration, wound 
healing, and tissue remodeling throughout an individual’s life.  
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Some studies suggest that MET is associated with lymphedema. Finegold et al. (2012) 
searched for variants in primary lymphedema genes in women who developed lymphedema after 
their breast surgery at Magee Womens Hospital by using collected biological samples. The study 
identified a rare MET variant in a single case. Finegold et al. (2008) identified four rare variants 
in HGF and MET that may be causative of developing secondary lymphedema. These truncation 
or missense mutations were only found in the cases with secondary lymphoma and not identified 
in any of the controls.  
1.2.3 Secondary Lymphedema 
Secondary lymphedema is an acquired condition. This complication occurs when there is 
damage to the lymphatic vessels or lymph nodes. This trauma to the lymphatic system causes the 
lymph fluid to be unable to flow properly throughout the body.  
1.2.3.1 Causes of Secondary lymphedema 
There are multiple known causes of secondary lymphedema; however, any trauma to the 
lymphatic system may lead to symptoms.  
Surgery is a common cause of lymphedema, particular surgeries that include removal of a 
particular lymph node. Women diagnosed with breast cancer often undergo surgical procedures 
involving the sentinal or axillary lymph nodes. Examining the lymph nodes assists with 
determining if the cancer may metastasize to other regions of the body. Tumor cells can travel 
through the lymphatic system. Looking at lymph nodes nearby the cancer site can help determine 
the likelihood of metastasis.  Sentinal lymph nodes are located near the breast and are the first 
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lymph nodes to which tumor cells may migrate to. Axillary lymph node are located near the 
breast and armpit. Axillary lymph node dissection usually removes between five and thirty nodes 
to determine the metastasis ability of the cancer (Lymph Node Removal for Invasive Breast 
Cancer, 2015).  
Cancer and radiation treatment may also cause secondary lymphedema. Depending on the 
location of the tumor, cancer cells may grow to cause a block in the lymphatic vessels. Radiation 
may cause harm to lymph nodes. Radiation can cause both scarring and/or inflammation of 
lymphatic cells. This inflammation may lead to a block in normal lymph flow (Lymphedema 
(PDQ), 2014).  
Certain types of infections may also lead to the development of secondary lymphedema. 
Whether bacteria, fungal, or parasitic, certain infections may lead to restriction of lymph flow. 
This is more common in developing countries, particularly those in tropical regions of the world. 
A common parasite that causes lymphedema is Wuchereria bancrofti.  These worms are spread 
through mosquitos and cause a condition known as Elephantitis, a severe form of lymphedema.  
1.2.3.2 Treatment 
Currently there is no cure for lymphedema. Certain treatment is used in order to help manage the 
swelling and pain symptoms; however, nothing is available to completely eliminate this 
condition. Physical therapy is often recommended in order to encourage movement of the 
affected limb. This movement may assist with lymph drainage in order for help the patient to 
pursue every day activities. Wrapping the limb or wearing a compression garment may help 
force lymph to flow away from the blockage. Manual drainage of the lymph fluid may occur 
after massaging the limb; however, this technique may lead to other complications such as pain 
and infection. Pneumatic compression is another form of treatment for lymphedema. Pneumatic 
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compression treatment involves having the patient wear a sleeve on their affected limb. This 
sleeve is attached to a pump that sporadically fills with air in order to put pressure on the limb. 
This is done to divert the lymph from the blockage.  These treatments may be combined to help 
reduce symptoms (Chiu, 2014). 
1.2.4 Post Mastectomy Pain Study 
In 2010 the University of Pittsburgh Department of Anesthesiology started a large pain 
phenotyping study in patients who had undergone a total or partial mastectomy at Magee 
Women’s Hospital of UPMC, using the Breast Cancer Registry and Banking Study. 
Clinical/medical information and tissue, whole blood, or saliva sample were obtained for each 
patient. The patient was then interviewed on chronic pain and related symptoms by phone six 
months after their breast surgery. Pain and psychosocial data were collected using standardized 
validated questionnaires. In addition, a survey on lymphedema symptoms developed by 
University of Pittsburgh Department of Human Genetics and validated in Lymphedema Family 
Study was applied to each patient.  A recently published paper from this study (using data from 
the first 600 subjects recruited) reported that psychosocial factors were more strongly related to 
persistent post mastectomy pain then the surgical treatment the patient initially received 
(Schreiber et al, 2012). The current study used the data already collected in the ongoing study (for 
1300 subjects as of April 2014) to identify secondary lymphedema cases. Biological samples 
from these cases and matched lymphedema-free patients were already available (obtained from 
the Magee Tissue bank) and were used for DNA isolation and genetic data collection. 
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1.2.5 Significance 
Approximately 300,000 new breast cancer cases are identified each year in the United States, the 
majority being invasive breast cancer (American cancer society, 2013) . Many women chose to 
have total or partial mastectomy to treat the diagnosed cancer or as a preventative option; 
however, having a breast surgery can cause other medical concerns. Post breast surgery patients 
are at risk for experiencing secondary lymphedema and chronic persistent pain, the reasons for 
which are still unexplained. A research proposal that aims to identify genetic factors associated 
with these significant complications will be greatly important for future breast cancer patients 
who are deciding which course of treatment is best. These risk factors could eventually predict 
which women are at risk for developing serious complications post-surgery. Knowledge of 
genetic predictors may affect clinical decision-making on optimal treatment strategies, and may 
lead to increased health and quality of life for patients at Magee and elsewhere.  
Secondary lymphedema is a serious condition that commonly transpires in cancer 
patients, particularly breast cancer patients, due to the removal or damage of lymph nodes as a 
part of surgical treatment. Previous studies reported that the incidence of developing secondary 
lymphedema after partial or total mastectomy is up to 33% (Hayes et al., 2008) Patients that 
experience lymphedema can suffer from decreased flexibility, limited limb mobility, increased 
limb weight, and skin hypersensitivity in areas where swelling occurs. Common complaints in 
patients with lymphedema include chronic pain and poor quality of life (Shigaki et al, 2013).  
Although secondary lymphedema is a common complication among cancer patients, molecular 
mechanisms underlying this condition are understudied and not completely understood including 
the role of genetic factors. Furthermore, it is currently unclear if primary and secondary 
lymphedema share a genetic background or common pathways. 
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This study aims to evaluate the role of selected candidate genes, GJC2 and MET, for 
developing secondary lymphedema in patients after breast surgery. Identifying genetic factors 
that may contribute to the susceptibility of secondary lymphedema has clinical relevance: if a 
screening procedure can be implicated to determine individuals that are at risk for developing 
secondary lymphedema, doctors can alter particular treatments, monitor patients more closely 
post-surgery, and implement novel preventive strategies in target patients. 
Although some evidence points towards the impact of GCJ2 and MET on the 
development of secondary lymphedema, it is currently unknown if their common SNPs 
contribute to secondary lymphedema and related phenotypes. These SNPs may potentially be 
used as predictive factors in screening testing. Understanding if these specific variants have a 
negative effect on an individual’s psychosocial phenotype may provide information for patient 
and physician and allow for supportive mental health services to be recommended for patients.  
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2.0  MATERIALS AND METHODS 
This thesis project was reviewed by the University of Pittsburgh’s Institutional Review Board 
and approval was obtained (Appendix A).  
2.1 DATA COLLECTION 
2.1.1 Patient Population 
The patient population consists of females from the Magee Women’s Hospital Post Mastectomy 
Pain study. In order to be eligible for the Post Mastectomy Pain study women had to have 
undergone either a total or partial mastectomy at Magee Women’s Hospital for the treatment of 
breast cancer. Participants in the secondary lymphedema project were selected from a larger 
sample population of approximately 1300 individuals who had completed a telephone survey six 
months after their breast surgery. The selection of cases and controls was made based on surgical 
and clinical information obtained through electronic records and patient answers to the study’s 
validated survey questionnaire.  The case group was defined as having secondary lymphedema 
symptoms. A diagnosis of secondary lymphedema was based on survey data obtained via 
structured phone interview or from electronic records. Matched controls for each individual case 
were then selected. The categories selected to match the cases to the controls were menopausal 
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status, age, body mass index (BMI), race, type of surgical treatment, type of adjuvant therapies. 
In cases where there was not a match in all of the five categories, age (menopausal status), node 
surgery, and treatment were prioritized.   
2.1.2 Informed Consent 
Informed consent was obtained for each participant involved in the Post Mastectomy Pain Study 
prior to any sample collection, survey, or review of medical records. In order to obtain consent 
from the participants the physicians performing the breast surgeries at Magee Women’s Hospital 
of Pittsburgh described the goals and eligibility requirement for participation in the study. The 
patients were also informed of their rights to withdraw from the study at any time. Although the 
Post Mastectomy Pain Study had minimal risk, any risks and benefits associated with the study 
were explained in detail (Appendix B).  The patient received a copy of the consent form for 
future reference and the contact information of the principle investigator, Dr. Inna Belfer. Only 
after receiving a signed consent form was the patient enrolled in the study, and a DNA sample 
requested from the participant or the Tissue Bank. Telephone surveys were conducted 6 months 
after the patient received their breast surgery.  
2.1.3 Samples: DNA Extraction 
DNA isolation and purification was performed on saliva, tissue, or blood samples by means of the 
protocol for the Qiagen extraction kits.  
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2.1.4 Survey 
Each patient participated in a 30-60 minute telephone survey. A copy of the full survey can be 
found in Appendix C.  
2.1.4.1  Distribution 
All surveys were conducted via telephone interview no earlier than 6 months after the 
participant’s breast surgery. The surveys were conducted by student researchers who had 
extensive training in conducting the phone interviews in order to maintain consistency. Each 
telephone interview was approximately 45 minutes in length.  
2.1.4.2 Pain Catastrophizing Scale (PCS)  
Multiple questions in the survey were asked in order to measure the emotional severity of an 
individual’s pain after breast surgery. The validated Pain Catastrophizing Scale measures the 
catastrophic thinking regarding any experienced pain.  A total of fourteen questions regarding an 
individual’s thoughts and feelings regarding the experienced pain were asked to each participant. 
Each individual question was scored on a scale from 0 to 4.  Scores of 0 indicated the most 
positive experience and scores of 4 indicated the most negative thoughts in regards to the pain. 
Each patient received an overall pain catastrophizing score ranging from 0 to 56. The score is 
directly related to the negative impact the pain has on the individual’s emotions (Van Damme S et 
al, 2002).  
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2.1.4.3 Perceived Stress Scale (PSS) 
The Perceived Stress Scale inquires about the frequency of instances in which an individual felt 
stressed within the past month prior to the survey. These specific questions are focused on 
understanding the level of stress that the participant is experiencing. This set of questions is a 
validated psychological instrument for measuring nonspecific stress in individual. The survey 
consists of ten questions all pertaining to participants’ emotions and ability (or inability) to 
control certain aspects of their lives. Each individual question was scored on a scale from 0 to 4.  
Scores of 0 indicated the most positive experience and scores of 4 indicated the most negative 
thoughts in regard to the stress. Each patient received an overall PSS score ranging from 0 to 40. 
The score is directly related to the negative impact that such stress has on the individual’s well-
being.  
2.1.4.4 Brief Pain Inventory (BPI)  
BPI measures each participant’s pain levels within the past week of the conducted interview.  
Questions include the present pain level, the average pain level, the lowest pain level, and the 
most intense pain level. The BPI score also consists of multiple questions pertaining to the effect 
that an individual’s pain has on everyday activities including general activity, mood, walking 
ability, occupation, relationships, sleep, and enjoyment of life, recreational activities, self-care, 
and social activities. Each individual question was scored on a scale from 0 to 10.  Scores of 0 
indicated no pain or that the pain does not interfere with the specific activity while scores of 10 
indicated the highest level of pain or that the pain completely interferes with the activity.  Each 
participant received an overall BPI score ranging from 0 to 140. The number is directly related to 
the negative impact the pain has on the individual (Dworkin RH et al, 2005).  
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2.1.4.5 Emotional distress (Anxiety PROMIS) 
The level of anxiety that an individual experienced after their breast surgery was measured based 
on the participants’ answers to seven specific questions regarding anxious feelings and attention 
span. This questions were part of the short-form instruments from the National Institute of 
Health roadmap initiative, Patient Reported Outcome Measurement Information System 
(PROMIS). This set of questions that measures the anxiety level has been validated in previous 
studies of large sample populations. Each individual question was scored on a scale from 1 to 5.  
Scores of 1 indicated the most positive experience and scores of 5 indicated the most 
unsatisfying experience regarding anxiety. Each patient received an overall anxiety score ranging 
from 7 to 35. The number is directly related to the level of anxiety (Cella D, et al, 2010).     
2.1.4.6 Emotional Stability (Depression PROMIS) 
Depression levels were also measured by means of short-form instruments from the Patient 
Reported Outcome Measurement Information System, otherwise known as PROMIS, which was 
established as a National Institute of Health roadmap initiative.  The individuals’ experience with 
depression after their breast surgery was measured based on their answers to eight specific 
questions regarding specific emotions and self-worth. This set of questions that measure the 
depression are also well validated. Each individual question was scored on a scale from 1 to 5.  
Scores of 1 indicated the most positive experience and scores of 5 indicated the highest level of 
depression. Each patient received an overall depression score ranging from 8 to 40. The score is 
directly related to the level of anxiety (Cella D, et al, 2010).   
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2.1.4.7 Sleep Disturbances (PROMIS) 
The quality of sleep that an individual experienced after their breast surgery was measured based 
on the participants answers to eight specific sleep-related questions. This questions were part of 
the short-form instruments from the National Institute of Health roadmap initiative, Patient 
Reported Outcome Measurement Information System (PROMIS). This set of questions that 
measure sleep disturbance has been well validated in previous studies of large sample 
populations.  Some questions were regarding the general quality of the sleep and other questions 
regarded the length of sleep. Each individual question was scored on a scale from 1 to 5.  Scores 
of 1 indicated the most positive experiences and scores of 5 indicated the most unsatisfied 
experiences regarding sleep. Each patient received an overall sleep disturbance score ranging 
from 8 to 40. The score is directly related to the negative quality of sleep experienced (Buysse, 
DJ et al, 2010) (Cella D, et al, 2010).    
2.2 SNP GENOTYPING 
2.2.1 SNP Selection 
Three major criteria were used in order to select each SNP used in this current study. First the 
SNP had to be commercially available due to the study’s financial limitations. The second 
criteria for selection of the SNPs was the reported minor allele frequency. The sample size only 
consisted of 163 participants; therefore, selecting a rare SNP with a very low minor allele 
frequency would be under powered to detect association. The final major criteria used to 
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determine which SNPs to select for the current study was the observed linkage disequilibrium 
with other SNPs in the gene in order to achieve adequate coverage for each gene.  
Three SNPs of the GJC2 gene were selected for the current study. SNP rs7523917, SNP 
rs11800309, and SNP rs7539762 all had reported minor allele frequencies higher than of .10 
(.34, .18, and .30, respectively).  In addition to the minor allele frequencies, this three SNP 
combination captures 17 of 33 sites (51% of the information) at R2 ≥ 0.8 according to the 
HapMap project.  
SNP rs41737 and SNP rs13223756 were selected for the MET gene. The reported minor 
allele frequencies for SNP rs41737 and SNP rs13223756 were 0.3756 and 0.1873, respectively. 
When combining rs41737 and rs13223756 less than 30% of MET gene coverage was obtained 
according to the HapMap Proxy.  
2.2.2 Setup of Plate 
Each plate consisted of both samples from cases and controls. In order to ensure consistency, the 
plates were set up to have both inter-plate and intra-plate controls. Figure 1 shows the plate setup 
for this study. All shaded areas in Figure 1 represent samples that were used as inter-plate and 
intraplate controls. The two plates contained both cases and controls in order to ensure 
consistency between plates.   
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 Figure 1: Plate Setup 
2.2.3 Genotyping  
SNP Genotyping was conducted using the TaqMan method, with ABI pre-designed assays and 
an ABI StepOne machine. 
2.3 STATISTICAL ANALYSES 
Statistical analysis was carried out using the R-studio statistical program.  Logistic regression 
was conducted in order to assess genetic SNP variants, demographic information, pain 
assessment, and psychosocial concerns in regards to the development of secondary lymphedema.  
The dependent variable was the development of secondary lymphedema and the independent 
variables included the genotype for each of the five SNPs, psychological pain scoring (brief pain 
inventory (BPI), sleep disturbances, perceived stress scale (PSS), anxiety, depression, sleep 
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disturbances, pain catastrophizing scale (PCS)), and demographic information (age, race, body 
mass index, and menopause status). Linear regression and Spearman correlation was performed 
to compare the effect of the genetic variants on the varying psychosocial phenotypes (Kuzma, J 
and Bohnenblust, S., 2005).   
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3.0  RESULTS 
3.1 DESCRIPTIVES 
Subjects were all Caucasian females between the ages 30-84 with 163 total participants. The age 
was defined as the age of the participant at the time of their breast surgery with an average age of 
54.59 (SD =11.88). All participants participated in a telephone interview which measured 
different experiences with pain, stress, anxiety, depression, and sleep disturbances. Sample 
characteristics including means, ranges and standard deviations were calculated for age, body 
mass index, and brief pain inventory, perceived stress, pain catastrophizing, anxiety, depression, 
and sleep disturbance scores (Table 1).   
Table 1: Descriptive Statistics for age, body mass index, pain, and psychosocial measurement 
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All participants participated in the Post mastectomy Pain Survey conducted by means of 
a telephone interview which measured different experiences with pain, stress, anxiety, 
depression, and sleep disturbances. Body mass index was calculated by obtaining weight and 
height measurements form the electronic medical records.   
The pain analysis and psychosocial measurements questions were separated into six 
different measurements (brief pain inventory (BPI), perceived stress scale (PSS), pain 
catastrophizing scale (PCS) anxiety PROMIS, depression PROMIS, and sleep disturbance 
PROMIS). For all of these, the higher values indicate a negative impact. The scores for the 
psychosocial phenotypes were not observed to follow a normal distribution pattern (Figure 2) 
 
 
Figure 2: Psychosocial Phenotype Distribution 
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 Sample frequencies were calculated for the development of lymphedema, onset of 
menopause, and type of node surgery (Table 2). Participants’ type lymph node surgery and 
menopausal status were obtained via electronic medical records. The diagnosis of lymphedema 
was obtained from either electronic medical record or from the Post Mastectomy Pain Survey.  
The sample population consisted of 48.17% of individuals who developed secondary 
lymphedema symptoms and 51.83 % of individuals without the development of symptoms at the 
time of the survey. About 34.76% of patients were premenopausal or perimenopausal and 
65.24% were post-menopausal from either natural menopause or as a result of surgery or 
chemotherapy. Approximately 30.67% of participants had axillary node dissection performed, 
45.40% with sentinal node dissection performed, 10.43% had both sentinal and axillary node 
dissection, and 13.50% had no lymph node dissection.  
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 Table 2: Frequencies of lymphedema, menopause, and lymph node surgery 
 
Participants’ genotype frequencies were calculated for each of the SNPs (Table 3). 
Genotypes were classified as 1/1 (homozygous for major allele), 1/2 (heterozygous), and 2/2 
(homozygous for minor allele). For SNP rs41737 the frequencies of adenine homozygotes, 
adenine and guanine heterozygotes, and guanine homozygotes at that specific base pair location 
were 16.30%, 45.10%, and 38.60%, respectively. For SNP rs7523917 the frequencies of adenine 
homozygotes, adenine and guanine heterozygotes, and guanine homozygotes at that specific base 
pair location were 11.40%, 48.40%, and 40.20%, respectively. For SNP rs7539762 the 
frequencies of cytosine homozygotes, cytosine and thymine heterozygotes, and thymine 
homozygotes at that specific base pair location were 10.40%, 51.10%, and 38.50%, respectively. 
For SNP rs11800309 the frequencies of guanine homozygotes, guanine and thymine 
heterozygotes, and thymine homozygotes at that specific base pair location were 58.40%, 
26 
35.70%, and 5.90%, respectively. For SNP rs13223756 the frequencies of adenine homozygotes, 
adenine and guanine heterozygotes, and guanine homozygotes at that specific base pair location 
were 61.40%, 32.10%, and 6.50%, respectively. 
Table 3: Genotype Frequencies by SNP 
 
3.2 ANALYSIS OF SNP GENOTYPE AND PSYCHOSOCIAL PHENOTYPES AS 
PREDICTORS OF SECONDARY LYMPHEDEMA 
For each SNP logistic regression was performed in order to determine if the genotype of the 
participant is associated of the development of lymphedema (Table 4). For this calculation the 
development of lymphedema was the binary dependent variable. The independent or predictive 
variables include the genotype, age, menopause, sentinal lymph node surgery, axillary lymph 
node surgery, and BMI were adjusted for in the calculation that evaluation each SNP. 
SNP rs41737, rs7523917, SNP rs7539762, SNP rs13223756 were not statistically shown 
to have a predictive influence on the development of lymphedema. SNP rs11800309 was 
significant (ά=.1) for being a predictor for the development of lymphedema in the sample 
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population. The beta coefficient (β) for SNP rs11800309 was calculated to be -0.5460, meaning 
that the development of lymphedema is indirectly related to the number of minor alleles present 
in an individual. The odds ratio was calculated to be .573.  
The psychosocial phenotype scores of participants were also compared to the 
development of lymphedema after being adjusted for age, BMI, menopause status, and lymph 
node surgery. PSS, BPI, anxiety, depression, and sleep disturbances were all observe to have no 
significant effect on the development of lymphedema. PCS was found to be a statistically 
significant (ά=0.1) predictor of lymphedema in this sample population. The PCS Score in a 
patient was observed to be directly related (β= 0.043) to the development of lymphedema with 
an odd ratio of 1.0439.  
Table 4: Logistic Regression: Lymphedema, Genotype, and Psychosocial Phenotype 
 
3.3 THE DEMOGRAPHIC EFFECT ON THE DEVELOPMENT OF LYMPHEDEMA 
Logistic regression was performed to observe the effect of the demographic information on the 
development of lymphedema. Univariate analysis (simple logistic regression) was performed for 
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each category of demographic information (age, menopause status, BMI, sentinal lymph node 
surgery, and axillary lymph node surgery) separately in order to observe the unadjusted effect 
(Table 5). Multivariable analysis was also performed in order to observe the adjusted effect that 
the demographic information has on the development of lymphedema (Table 6). For both models 
significant associations between demographic information and the outcome of lymphedema were 
not observed.  
Table 5: Univariate analysis: Demographics on lymphedema development 
 
Table 6: Multivariable Analysis: Demographics effect on lymphedema development 
 
3.4 LINEAR REGRESSION AND SPEARMAN TEST: GENOTYPE AND 
DEMOGRAPHIC EFFECT ON PSYCHOSOCIAL PHENOTYPES 
This current study aimed to determine if the genotype and demographic information had an 
effect on the psychosocial phenotype.  For evaluation of each psychosocial phenotype linear 
regression, demographic multivariable analysis, demographic univariate analysis, and the 
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Spearman Correlation test were performed. Linear regression was performed with the SNP 
genotypes being the predictor. These analyses were adjusted for the effects of age, menopause 
status, BMI, sentinal node surgery, and axillary node surgery.  Univariate and Multivariable 
analysis were performed to determine the effect of the demographic information. The 
psychosocial phenotypes were not normally disturbed, which makes the reliability of the linear 
regression less than ideal. Spearman Correlation Test was also performed for each genotype and 
demographic information for each separate psychosocial feature in order to account for the 
screwed distributions.  
3.4.1 Brief Pain Inventory (BPI) 
For SNP rs7523917, SNP rs7539762, SNP rs11800309, and SNP rs13223756 no statistically 
significant predictive effects was observed when comparing these genotypes to the BPI scores in 
individuals. SNP rs41737 showed a statistically significant predictive effect on BPI scores 
(ά=.05). The beta coefficient was observed to be 6.9165 indicating that individuals with two 
minor alleles are more likely to have higher BPI scores. Demographic information affect was 
adjusted for when using this static model (Table 7). The reliability and interpretation of this test 
is limited because the BPI score is not normally distributed.  
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Table 7: Linear Regression for BPI and Genotype 
 
 Linear regression was performed to observe the effect of the demographic information on 
the BPI scores. Univariate analysis (simple logistic regression) was performed for each category 
of demographic information (age, menopause status, BMI, sentinal lymph node surgery, and 
axillary lymph node surgery) separately in order to observe the unadjusted effect (Table 8). 
Multivariable analysis was also performed in order to observe the adjusted effect that the 
demographic information has on BPI scores (Table 9).  Both different calculation failed to 
observe significant association between menopause status, BMI, sentinal Node lymph node 
surgery, and axillary lymph node surgery on BPI scores. Age was observed to be statistically 
significant for predicting BPI scores in both the Univariate (ά= .1) and Multivariable (ά= .05) 
statistic models. Both models showed that age was indirectly related to the BPI score (β=-.53449 
and -2949). The reliability and interpretation of these tests is limited because the BPI score is not 
normally distributed. 
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Table 8: Multivariable analysis Demographics on BPI 
 
Table 9: Univariate analysis: Demographics on BPI 
 
 A non-parametric test was performed because of the non-normal distribution of the BPI 
scores (Table 10). Spearman correlation test indicates that rs41737 genotype is correlated with 
BPI scores. The significance level for this comparison was observed to be .03932 and rho to be 
.167. All other data did not show significant correlations for BPI scores.  
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Table 10: Spearman Test: BPI 
 
3.4.2 Perceived Stress Scale (PSS) 
For SNP rs7523917, SNP rs7539762, SNP rs11800309, and SNP rs13223756 no statistically 
significant predictive effect was observed when comparing these genotypes to the PSS scores in 
individuals. SNP rs41737 indicates a statistically significant predictive effect on PSS scores 
(ά=.05). The beta coefficient was observed to be 1.68709 indicating that individuals with a minor 
allele are more likely to have higher BPI scores. Demographic information effect was adjusted 
for when using this statistic model (Table 11). The reliability and interpretation of this test is 
limited because the PSS score is not normally distributed.  
33 
Table 11: Linear Regression for PSS and Genotype 
 
Linear regression was performed to observe the effect of the demographic information on 
the PSS scores. Multivariable analysis was also performed in order to observe the adjusted effect 
that the demographic information has on the PSS scores (Table 12).  Univariate analysis was 
performed for each category of demographic information separately in order to observe the 
unadjusted effect (Table 13). For both models significant association of BMI, sentinal lymph 
node surgery, and axillary lymph node surgery on PSS scores were not observed. Age was 
observed to be statistically significant for predicting PSS scores in both the Univariate and 
Multivariable (ά= .001) statistic models. Both models showed that age was indirectly related to 
the BPI score (β=-.53449 and -2949). Menopause was also shown to have a similar effect on PSS 
scores. Menopause was observed to have a significant effect on PSS in both models at a .05 ά 
level. When linear regression was performed for menopause as the only predictor a negative 
trend was observed (β= -2.1487), indicating that women who have not experienced menopause 
scored had higher stress levels. When age, BMI, and lymph node was adjusted for the calculation 
showed a positive trend for menopause (β=3.66098). The reliability and interpretation of these 
tests is limited because the BPI score is not normally distributed. 
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Table 12: Multivariable analysis demographics on PSS 
 
Table 13: Univariate analysis: Demographics on PSS 
 
A non-parametric test was performed because of the PSS scores do not follow normal 
distribution patterns (Table 14). Spearman correlation test indicates that age is correlated with 
PSS scores. The significance level for this comparison was observed to be 7.465e-05 and rho to 
be -.3052. All other data did not show significant correlation for PSS scores. 
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Table 14: Spearman Test: PSS 
 
3.4.3 Pain Catastrophizing Scale (PCS) 
All SNPs (SNP rs41737, SNP rs7523917, SNP rs7539762, SNP rs11800309, and SNP 
rs13223756) were not observed to be statistically significant predictors for PCS scores (Table 
15). For this model the effect of demographic information was adjusted. The reliability and 
interpretation of this test is limited because the PCS scores do not follow normal distribution.   
Table 15: Linear Regression for PCS and Genotype 
 
Linear regression was performed to observe the effect of the demographic information on 
the PCS scores. Multivariable analysis was also performed in order to observe the adjust effect 
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that the demographic information has on the PCS scores (Table 16).   Univariate analysis was 
performed for each category of demographic information separately in order to observe the 
unadjusted effect (Table 17). Age was observed to be statistically significant for predicting PCS 
scores in both the Univariate and Multivariable observations with ά= .01. Both models showed 
that age was indirectly related to the PCS scores (β= -.23038 and -.18011). Whether an 
individual had sentinal node surgery performed was observed to have a significant effect on the 
PCS scores when using the unadjusted univariate model (ά=.05). Sentinal lymph node surgery’s 
effect on PCS was observed have a negative trend (β= -3.275).  The reliability and interpretation 
of these tests are limited because the BPI score is not normally distributed. 
Table 16: Multivariable analysis of demographics on PCS 
 
Table 17: Univariate analysis of demographics on PCS 
 
A non-parametric test was performed because of the non-normal distribution of the PCS 
scores (Table 18). Spearman correlation test indicates that axillary node dissection is correlated 
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with PSS scores. The significance level for this comparison was observed to be .003765 and rho 
to be .2264137.  All other data did not show significant correlation for PCS scores. 
Table 18: Spearman Test on PCS 
 
3.4.4 Anxiety 
Linear regression was performed for each SNP to measure the predictability effect the genotypes 
have on anxiety scores. The effects of demographic information were adjusted for when using 
this statistic model (Table 19). Two SNPs (SNP rs7539762 and SNP rs11800309) were observed 
to have a significant effect on the anxiety score of an individual. SNP rs7539762 was significant 
(ά=.047501) and showed a positive trend with minor allele frequency (β=1.54650). SNP 
rs11800309 was significant (ά=.0987) and showed a negative trend with minor allele frequency 
(β=1.33464). SNP rs7523917, SNP rs13223756, and SNP rs41737 were not shown have 
statistically significant predictive effect on Anxiety scores in this sample population. The 
reliability and interpretation of this test is limited because the anxiety scores are not normally 
distributed.  
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Table 19: Linear Regression for Anxiety and Genotype 
 
For demographic information, linear regression was performed to observe their effect of 
on the anxiety scores. Multivariable analysis was also performed in order to observe the adjusted 
effect that the demographic information has on anxiety (Table 20).  Simple logistic regression 
was performed for each category of demographic information separately in order to observe the 
unadjusted effect (Table 21). For both models significant association between menopause status, 
BMI, sentinal lymph node surgery, and axillary lymph node surgery on anxiety scores were not 
observed. Age was observed to be statistically significant for predicting anxiety scores in both 
the Univariate (ά= .001) and Multivariable (ά= .01) statistic models. Both models showed that 
age was indirectly related to the anxiety score (β=-.15757 (multivariable) and -.13214 
(univariable)). Menopause was significant at a .1 significant and showed a negative trend when 
other demographics were unadjusted. The reliability and interpretation of these tests are limited 
because the anxiety score is not normally distributed. 
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Table 20: Multivariable analysis of demographics on Anxiety 
 
Table 21: Univariate analysis of demographics on Anxiety 
 
A non-parametric test was performed anxiety scores are not normal distribution (Table 
22). Spearman correlation test indicates that age is correlated with anxiety scores. The 
significance level for this comparison was observed to be .0006 and rho to be -.2664. All other 
data did not show significant correlation for anxiety scores. 
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Table 22: Spearman Test: Anxiety 
 
 
3.4.5 Depression 
SNP rs7523917, SNP rs7539762, SNP rs11800309, and SNP rs13223756 were observed to show 
no significant effect on predicting depression scores. SNP rs41737 was observed to have a 
statistically significant predictive effect on depression scores (ά=.0171). The beta coefficient was 
observed to be 2.0355 indicating that individuals’ depression scores are directly related to the 
amount of minor alleles (Table 23). The reliability and interpretation of this test is limited 
because the depression scores do not follow normal distribution.   
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Table 23: Liner Regression for Depression and Genotype 
 
Linear regression was performed to observe the effect of the demographic information on 
the depression scores. Multivariable analysis was also performed in order to observe the adjusted 
effect that the demographic information has on depression levels reported by the individual 
(Table 24). Univariate analysis was performed for each category of demographic information to 
determine the individual effect each categories has on depression (Table 25). Both models 
observe a significant effect of BMI on depression (ά=.0894 (multivariable) and ά=.08918 
(univariate)). Both models also observed a positive trend between BMI and depression scores. 
For the univariate model, age also was observe to have an effect on depression scores (ά=.0903) 
and showed a negative trend between age and depression (β=-.07128). For both models 
significant association between menopause status, sentinal lymph node surgery, and axillary 
lymph node surgery on depression scores were not observed. The reliability and interpretation of 
these tests is limited because the BPI score is not normally distributed. 
42 
Table 24: Multivariable analysis of demographics on Depression 
 
Table 25: Univariate analysis of demographics on Depression 
 
A non-parametric test was performed because of the non-normal distribution of the PSS 
scores (Table 26). Spearman correlation test indicates that SNP rs41737 and BMI are correlated 
with depression scores. The significance level for the correlation between SNP rs41737 and 
depression was observed to be .04701 and rho to be .1582705. The significance level for the 
correlation between BMI and depression was observed to be .0964 and rho to be .1447268.  All 
other data did not show significant correlation with depression scores. 
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Table 26: Spearman Test: Depression 
 
3.4.6 Sleep Disturbances 
Linear regression was performed to determine the predictive effect each SNP had on the sleep 
disturbance score for each participant. All SNPs (SNP rs41737, SNP rs7523917, SNP rs7539762, 
SNP rs11800309, and SNP rs13223756) were observed to show no statistically significant 
predictive effect on sleep disturbance. The effect of the demographic information was adjusted 
for when using this statistic model (Table 27). The reliability and interpretation of this test is 
limited because the sleep disturbance scores are normally distributed.  
Table 27: Linear Regression for Sleep and Genotype 
 
 Linear regression was performed to observe the effect of the demographic information on 
the sleep disturbance scores. Multivariable analysis was also performed in order to observe the 
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adjusted effect that the demographic information has on sleep (Table 28). Univariate analysis 
was performed for each category of demographic information in order to observe the unadjusted 
effect on sleep (Table 29).  Age was observed to be statistically significant for predicting sleep 
disturbance scores in both the Univariate (ά= .00785) and Multivariable (ά= .000614) statistic 
models. The univariate and the multivariable models showed that age was indirectly related to 
the sleep score (β=-.20464 and -.29263 respectively).  No significant association was observed 
between menopause status, BMI, sentinal lymph node surgery, and axillary lymph node surgery 
on sleep scores. The reliability and interpretation of these tests is limited because the sleep does 
not follow normal distribution.   
Table 28: Multivariable analysis of demographics on Sleep 
 
Table 29: Univariate analysis of demographics on Sleep 
 
A non-parametric test was performed because of the non-normal distribution of the sleep 
disturbance scores (Table 30). Spearman correlation test indicates that there is no significant 
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correlation between any of the genotype or demographic information with sleep disturbance 
scores.  
Table 30: Spearman Test: Sleep 
 
  
3.5 RESULTS SUMMARY 
SNP rs11800309 and PCS scores were observed to be significant predictors for the 
development of secondary lymphedema symptoms at a 0.1 significance level.  SNP rs41737 was 
observed to have significant effect on BPI scores when using both linear regression model and 
the Spearman Correlation test.  Age was observed to be significantly related to BPI scores with 
the linear regression models. SNP rs41737, age, and menopause had significant at effect on PSS 
scores when using the linear regression models. Age was also observed to have significant effect 
on PSS with the Spearman Correlation test.  Age was observed to have a significant effect on 
PCS scores when using multivariable and univariate linear regression models, as well as the 
Spearman Correlation test.  Sentinal lymph node dissection was observed to be related to PCS 
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scores in the univariate linear regression model. Axillary lymph node dissection was observed to 
be related to PCS scores when using the Spearman Correlation test.  SNPs rs7539762 and 
rs11800309, age, and menopause were observed to have a significant effect on anxiety scores 
when using the linear model.  Age was also observed to have a significant effect on anxiety when 
using the Spearman Correlation test. SNP rs41737 and BMI was observed to be related to 
depression scores when using both the linear regression and the Spearman correlation test. Age 
was observed to effect depression scores when using the univariate liner regression model only.  
Only age was observed to have a significant effect on sleep scores in the multivariable and 
univariate linear regression models.  
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4.0  DISCUSSIONS 
4.1.1 Aim I 
Multiple studies have identified persistent pain after surgery as a probable concern for 
women who undergo breast cancer. The prevalence of pain after breast surgery is estimated to be 
experienced in up to 50% of patients. Side effects from cancer treatment have a negative impact 
on the quality of life in the majority of cancer survivors (Andersen et al, 2011; Chebille AL and 
Tchou J, 2007; Maunsell E et al, 1993). Looking at all the subjects in the current study, many 
conclusions can be drawn from the different psychosocial measurements obtained.  
In the current study, the average brief pain inventory measurement was reported to be 
17.90, with the BPI testing scale ranging from 0-140. This average measurement is associated 
with a low or mild experience with pain in this sample population. The brief pain inventory 
measures the present level of pain, the average intensity of pain, the lowest level of recent pain, 
the highest level of recent pain, and the recent effect the pain has had on the participants’ daily 
activities. The majority of the participants in this study were observed not to be effected with 
recent pain, however, the overall range amongst those who participated was observed to be 0-
112. This suggests that this measurement is quite variable, with the minority of patients being 
significantly affected with high levels of pain.  
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Perceived stress was an additional measurement obtained from conducting the study 
survey. In the current study the average PSS measurement was reported to be 10.60, with the 
PSS testing scale ranging from 0-40. The sample mean suggest that the sample population 
“almost never” felt nervous, incapable of control, or overwhelmed within a month of the survey 
being conducted.  Although average participants in this study were observed not to be stressed 
the overall range amongst participated was observed to be 0-36. This again suggests that this 
measurement is quite variable among the sample population, with the minority of patient often 
affected with severe stress.  
Pain catastrophizing scale was an essential measurement to understand the patients’ 
general feeling, thought, and emotions regarding the effect of the experienced pain. The average 
score observed in this sample population was 5.28. This suggests that the participants were 
having negative feelings or thoughts about their pain either not at all or to a slight degree. The 
PCS range observed in this sample population is quite variable, ranging from 0-47. This suggests 
that some outliers in the sample experience negative thoughts to a great degree. 
Anxiety was also measured by means of the Anxiety short form. These seven questions 
measured the patients’ level of fear, worry, focus, and vulnerability within a week of the survey 
date. The results of the study show a mean score of 12.52, the testing range for anxiety was 7-35. 
This showed that the average patient rarely felt anxious feelings. The survey results were 
variable with a range from 7-32. Only a minority of participants were observed to have severe 
anxiety.  
Depression scores were calculated by means of an eight question survey. These questions 
measured negative feeling within the past week of the survey date. The results showed a mean 
score of 11.63, with the possible test scores ranging from 0-40.  The observed mean of 11.63 
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indicated that the participants rarely experienced these negative feelings of depression.  Ranges 
were very variable, however, with some participants reporting always having these feelings.  
Sleep quality and disturbances were also measured by means of an eight question survey. 
Although the ranges were variable, the average sample score indicates that participants are only 
somewhat satisfied with their sleep quality. When compared to the other psychosocial 
phenotypes, sleep disturbance was the measurement that was observed to have the majority of 
participants being not completely satisfied.  
Overall, these scores were lower than hypothesized in a sample population of women that 
have recently undergone breast cancer surgery; however, since both the cases and controls had 
undergone breast surgery it is impossible to say whether each specific mean score was higher 
than that of the general population. It is apparent that each score showed quite variable ranges. It 
would be both helpful and have an impact in the field of public health to determine the variables 
that cause differences in psychosocial phenotypes amongst the population in order to provide 
treatment, management, and care for the outliers in the population.  
4.1.2 Aim II 
SNP genotyping of common Single Nucleotide Polymorphisms (SNPs) in GJC2 and MET was 
performed on our sample population. For all of the SNPs in the current study, we observed 
participants that were homozygous for the major allele, homozygous for the minor allele, and 
individuals that were heterozygotes. The fact that both alleles were observed when genotyping 
made it possible to draw proper conclusions of genetic variant’s effect on the development of 
lymphedema and psychosocial phenotypes.   
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4.1.3 Aim III 
The analysis of information was broken down into three separate sections. The first part of the 
analysis was to determine if the SNPs genotypes were determining factors in the development of 
lymphedema. The second part of the analysis was to determine if the psychosocial phenotypes 
were associated of the development of lymphedema. The last part of the data analysis for the 
current study was to determine if genotype variation had an influence on the presenting 
psychosocial phenotypes. Demographic information was also considered in order to adjust for 
the effect of age, menopause, lymph surgery, and body mass index. 
Although no specific demographic feature was statistically significant at .05 level in 
contributing to the development of lymphedema, a few interesting observations can be drawn 
from this analysis. First, previous studies have observed that individuals who had axillary 
dissection or axillary sampling had an increased risk for developing lymphedema symptoms 
(Liljegren G and Holmberg, 1997). The current study did not find any correlation between 
lymphedema and axillary surgery. Perhaps this can be explained by the improvement of surgical 
techniques over time. Past studies have also reported a correlation with the development and the 
severity of lymphedema with obesity (Ridner SH et al, 2011). Again no significant correlation 
was observed between the development of lymphedema and an increased BMI. Although not 
significant as being a predictor, the data indicates age, BMI, and axillary node dissection follow 
the expected positive trends (increased BMI and age, and a history of axillary node surgery was 
observed to increase the risk of lymphedema).  
Another interesting conclusion drawn from the logistical regression analysis for the 
development of lymphedema and the genotype, is the results yielded from SNP rs1800309 of the 
GJC2 gene. Although not statistically significant at a .05 level, the p-value was observed to be 
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.0649 and the greatest predictor. Decreasing the confidence interval to 90%, SNP rs11800309 
was observed to have a significant effect. The beta coefficient was observed to be a negative 
value, indicating that the minor allele is in protective for developing symptoms of lymphedema. 
For this particular SNP located within the GJC2 gene at position 228391808, individuals with 
genotype G/T or T/T are less likely to develop lymphedema symptoms than individuals with the 
genotype G/G. The odds ratio for this association was observed to be .5793 indicating that 
individuals that have the G/T have approximately a half-fold decrease for developing 
lymphedema when compared to individuals with a G/G phenotype. These results also indicate 
that individuals that have the T/T have a half-fold decrease for developing lymphedema when 
compared to individuals with a G/T phenotype. With the limited sample size and some of the 
other study limitations, this particular SNP may require further studies in order to determine 
whether variation in this SNP is significant in the development of lymphedema.  
Interesting results were also observed when determining if the psychosocial phenotype is 
associated with the development of lymphedema. The Pain catastrophizing score was found to be 
significantly associated with lymphedema development. The PCS scores were positively 
associated with lymphedema, meaning that individuals with high PCS scores were more likely to 
have lymphedema symptoms. The odds ratio for this association was 1.0439, indicating for each 
increase in PCS score the odds of developing lymphedema increased by 1.0439. This data 
suggests that individuals that are experiencing high levels of severe emotional response to pain 
should be observed closely by their physician for lymphedema. Also, patients with lymphedema 
may benefit from counseling services. Further studies, with a larger sample size, may be 
warranted to better understand the relationship between PCS and lymphedema. 
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 When observing the relationship between lymphedema, BPI, PSS, anxiety, sleep, and 
depression, no significant relationships were identified.  Although not significant, positive trends 
were observed for BPI, depression, and anxiety while negative trends were observed for PSS 
scores and sleep disturbances.  
The last section of the current study aimed to determine whether the genotype had an 
influence on the psychosocial phenotypes of an individual. Multiple interesting conclusions were 
observed from this comparison.   
SNP rs41737 was observed to be statistically significant in predicting BPI, PSS, and 
depression scores at a .05 significance level.  The trends for BPI, PSS, and depression scores 
were observed to be positive, indicating that the minor allele is associated with increased pain, 
stress, and depression.  This positive association was observed in the linear regression models, 
which assumes normal distribution. All of these psychosocial phenotypes do not follow normal 
distribution; the psychosocial scores are all positively skewed. Spearman Correlation was also 
performed and SNP rs41737 showed significance, indicating the minor allele is correlated with 
increased pain, stress, and depression.  
SNP rs753962 was observed to be statistically significantly associated with anxiety 
scores at a .05 significance level.  The trend for anxiety and SNP rs753962 was observed to be 
positive, indicating that the minor allele is associated with increased anxiety.  This positive 
association was observed in the linear regression models, which assumes normal distribution. 
Anxiety does not follow normal distribution; it is skewed right. Spearman Correlation was also 
performed and did not show a significant correlation between SNP rs753962 and anxiety scores.  
SNP rs1180039 was observed to be statistically significant in predicting anxiety scores at 
a .1 significance level. The trend for anxiety and SNP rs1180039 was observed to be negative, 
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indicating that the minor allele is associated with decreased anxiety.  This negative association 
was observed in the linear regression models, which assumes normal distribution; however, 
anxiety does not follow normal distribution. Spearman Correlation was also performed and no 
statistically significant correlation between SNP rs1180039 and anxiety scores was observed.  
Effects of the demographic information on the psychosocial phenotypes were also 
observed in the current study. Age had a significant effect on all of the psychosocial phenotypes. 
Data indicates that the older an individual was at the time of their breast surgery, the less 
negative experience the individual will have with pain, stress, anxiety, depression, and sleep. It is 
challenging to interpret the explanation behind this observation. One possibility is that older 
individuals are less sensitive to pain. Another explanation may be that older generations are less 
inclined to express their true pain level due to cultural differences and fear of appearing more 
vulnerable. This correlation between age and all psychosocial phenotypes was observed when 
using the linear regression models. This correlation between age and psychosocial phenotypes 
was observed when using Spearman Correlation test for BPI, PSS, anxiety and depression.  
Women with a history of sentinal node dissection were statistically observed to have 
lower PCS scores. This observation was only statistically significant when using the univariate 
model. When adjusting for age, axillary surgery, BMI, and menopause status this association was 
not observed. When using the Spearman Correlation test, women with a history of axillary node 
dissection were statistically observed to have higher PCS scores. The interpretation of the effect 
of lymph node surgery is challenging. Axillary and sentinal node dissection seem to have no 
effect on any of the other psychosocial phenotypes. Perhaps a possible explanation for this 
observation is that women who had lymph node surgery were originally diagnosed with more 
aggressive invasive cancer than those who did not have lymph node surgery. Perhaps having a 
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more invasive cancer increases one’s PCS score because the individual is more fearful of future 
diagnosis. Further investigation should be conducted to add more insight to this observation.  
BMI was observed to be associated with higher depression scores at a significance level 
of .1. This was observed with the multivariable linear regression, univariate linear aggression, 
and Spearman correlation test. Multiple studies suggest that depression is more prevalent in 
individuals with higher BMI scores (Onyike CU et al, 2003). This study adds more evidence that 
BMI has an impact on the quality of life in individuals that are overweight.  
4.1.4 Public Health Significance 
The current study had identified information that may be relevant in identifying women who may 
be at an increased risk for developing secondary lymphedema after breast surgery.  The data 
shows that women who have high PCS scores were likely to also experience lymphedema 
symptoms. Whether lymphedema development is causative of developing this psychosocial 
phenotype is unknown. The correlation between pain catastrophizing and lymphedema is 
evidence that women with lymphedema have a lower quality of life than that of unaffected 
individuals. This data suggests the possible need for psychological services and resources to be 
offered to patients that have breast surgery, specifically individuals that go on to develop 
lymphedema. 
 This study also identified the genotype at SNP rs41737 to affect the pain, stress and 
depression levels. SNP rs41737 genotype was also identified to effect anxiety scores. Mental 
health concerns are a colossal challenge that effects the American population. According to the 
Center of Disease Control, approximately 8% of the American population suffers from 
depression in any two-week period (QuickStats: Prevalence of Current Depression , 2012).  Also, 
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according to the National Ambulatory Medical Care Survey and National Hospital Ambulatory 
Medical Care Survey, it is also estimated that major depressive disorders cost the American 
healthcare system 8.0 million dollars per year.  Mental health illness is a subject where not much 
is understood about the genetic contributions to this group of disorders. A larger study is 
warranted to see if variations within this gene increase the susceptibility for developing mental 
health issues, such as depression and stress. If larger studies can further validate these findings 
perhaps screening for higher susceptibility of depression can be implemented in order to assist 
individuals in receiving counseling services and resources. 
 Another significant finding in the current study was the common observation that BMI 
may lead to depression. BMI was not seen to affect anxiety levels, pain levels, stress levels, or 
the development of lymphedema. However, BMI measurements were observed to have an 
impact on higher depression scores.  Whether societies’ discrimination tendencies and 
stereotypes cause individuals that are obese to be more likely to experience symptoms of 
depression or whether depressed individuals are more likely to live unhealthy life styles that may 
lead to obesity is not indicated for this current study. Perhaps a third, unknown factor causes both 
depression and obesity. Causation cannot be determined from the current study; however, an 
association between BMI scores and depression was observed. Studies are consistently observing 
this same result. It is important that public awareness programs be initiated in order to educate 
the public about the effect obesity has on not just physical health concerns, but mental health 
concerns as well. Also, because of the increased risk for depression, counseling services should 
be offered to patients who are obese, especially in school settings, so that individuals can learn 
coping mechanisms earlier in life.  
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4.1.5 Limitations 
Throughout the course of the project, multiple limitations that may have impacted the outcome 
of the study were identified. These limitations include the sample size, case definition, selections 
of SNPs, selection of matched controls, limited information for some participants, and timing of 
the survey for certain patients.  
One of the major limitations of this study was the small sample size. Although the Post 
mastectomy Pain study database consisted of approximately 1,300 participants that completed 
surveys, the actual cases of physician diagnosed lymphedema was relatively small. Only a total 
of 85 participants were identified to have developed secondary lymphedema after their breast 
surgery based on physician diagnosis or self-reported treatment of lymphedema. 85 controls 
were included in the study making the total sample population 170 participants. When it came 
time to perform the data analysis, because the number of African American and/or Hispanic 
individuals was small and would be an unnecessary cofounding variable, these participants were 
eliminated from the study for simplicity. This decreased our total sample size to 164 participants 
(79 cases, 85 controls). Epidemiological studies estimate the incidence of lymphedema to range 
from 8-20% (Paskett ED, et al, 2007). Based on this estimate, it was expected that more cases 
would be identified. 
Another limitation to this study was the case definition. In ideal circumstances, the cases 
for this study would have included individuals with a physician confirmed diagnoses of 
secondary lymphedema. In order to have a large enough sample size for any results to be 
significant, the case definition was expanded to include individuals that had either a physician 
confirmed diagnoses of secondary lymphedema or experienced self-reported symptoms of 
lymphedema. It is challenging to predict the overall effect this limitation had on defining the 
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cases. Although lymphedema symptoms are often quite apparent to a patient, the study could not 
rule out false reports of lymphedema in the sample population. Another essential consideration 
when reviewing the case definition in secondary lymphedema cases after breast surgery is that 
these symptoms may not become apparent until years after the surgical therapy. These surveys 
were conducted after 6-months post breast surgery. Because it could take years to develop 
symptoms, it is possible that some of the controls in our study may have a diagnosis of 
lymphedema later in life. This would obviously have a large effect on the results of the study, 
particularly the genotype data. The main goal of the study was to identify a genetic or 
psychosocial difference between the case and control groups. To examine and interpret any 
difference it is essential that no cases pollute the control group.  
 Identifying a match control for each specific case was also another limitation for the 
study. The Post Mastectomy Pain Study database provided a multitude of possible cases, which 
allowed for the majority of the cases to be matched based on seven categories (menopausal 
status, age at surgery, body mass index, race, type of breast surgery, type of node dissection, and 
treatment). These particular categories were matched to each patient to limit the effect that 
cofounding variables would have on both the genetic and psychosocial results. A small 
proportion of cases did not have a perfect match in all of the seven categories. In these cases, 
age, menopausal status, type of surgery, and treatment were prioritized when selecting a match 
because these categories are major contributing factors to the development of secondary 
lymphedema.  
Another limitation in the study design was the fact that SNP genotyping was performed 
with a limited amount of SNPs for each gene. Due to limited funding, sequencing of the entire 
GJC2 and MET genes was not a viable option. According to NCBI, GJC2 is a gene that is made 
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up of 10,113 bases and the MET gene is made up of 125,997 bases. In the current study, only 
three of these bases for GJC2 and two bases for MET were examined. The HapMap Proxy 
estimated gene coverage by considering linkage disequilibrium.  For GJC2 only 50% of the gene 
was covered and less than 30% for MET. The low coverage is a major limitation in predicting 
whether or not these genes influence the development of secondary lymphedema or have an 
effect on the psychosocial phenotypes.  
Concerns involved in performing multiple comparison are another limitation of this 
current study. The psychosocial data did not follow normal distribution patterns; therefore, the 
linear regression results and interpretations are not reliable. The Spearman Correlation test was 
performed to determine if genotype and demographic information were correlated with 
psychosocial scores; however these results are not adjusted. The trends identified in this study 
are not significant when viewed in context of the whole project2.  
The time in which the survey was conducted was another inconsistency in the study 
design. An attempt to contact each patient was made six months after receiving breast surgery; 
however, not all participants were available at the time the student researcher made the telephone 
call. Some of the participants were not interviewed until much later than six months after their 
breast surgery. Although this inconsistency may not have had a substantial effect on the study, it 
is important to recognize this inconsistency as having a possible effect on the pain and 
psychosocial phenotypes.  
Missing survey information for certain participants was another set-back for the project. 
This was in relatively rare situations; however, certain parts of the survey were unanswered on 
occasion. This drawback was limited due to the consistency of the interviewers. When a 
psychosocial question was not answered by a participant the scoring was adjusted in order to 
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compensate for the limited information. This compensation was implemented by multiplying the 
total score of each measurement by the total amount of answered questions. This number was 
than divided by the total amount of questions for that part of the survey. This method ensured 
that each score containing unanswered questions would be adjusted.  
 
4.1.6 Future Research 
Lymphedema and the lymphatic system are, in general, understudied. More studies are needed in 
order to help determine which patients are susceptible to this condition and which are not. Full 
sequencing of all the genes known to cause primary lymphedema should be performed on 
participants that are affected with secondary lymphedema to better determine if any of these 
genes contribute to the development of symptoms. Full sequencing of these genes would allow 
coverage of the entire gene and would be able to identify if any specific variant is evident in 
lymphedema patients. It would also be beneficial to have a larger sample to increase statistical 
power to detect associations. This would allow a more detailed examination of these genes’ 
contribution to lymphedema.   
This current study identified certain SNPs being correlated to a negative psychosocial 
phenotype. Mental health illness is a major concern in the American population.  It would be 
interesting to perform a similar study with the sample consisting of participants from the general 
population (not suffering from breast cancer). Particularly, SNP rs41737 was observed to be 
statistically significant in predicting BPI, PSS, and depression scores at a .05 significance level.  
It would be interesting to examine the general population for this same variant and measure the 
depression score to determine if this gene is associated with higher depression rates. SNP 
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rs1180039 and SNP rs753962 were associated with higher levels of anxiety. It would be valuable 
to observe whether or not these symptoms contribute to psychosocial phenotypes in other 
populations. Perhaps these studies may provide information for screening individuals for mental 
health concerns in order to ensure people receive proper medical care.  
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APPENDIX A: IRB APPROVAL 
3500 Fifth Avenue 
University of Pittsburgh Pittsburgh, PA 15213(412) 383-1480 
Institutional Review Board (412) 383-1508 (fax) http://www.irb.pitt.edu 
Memorandum 
To: Inna Belfer 
From: IRB Office 
Date: 11/28/2014 
IRB#: REN14110253 / PRO09090125 
Subject: Cross-sectional Study on Postmastectomy Pain Genetics and Prognostic Value of 
Therapeutic Procedures  
 
Your renewal for the above referenced research study has received expedited review and 
approval from the Institutional Review Board under: 
45 CFR 46.110.(4) 
45 CFR 46.110.(5) 
45 CFR 46.110.(7) 
Please note the following information:  
Approval Date: 11/28/2014 
Expiration Date: 11/27/2015 
Please note that it is the investigator’s responsibility to report to the IRB any 
unanticipated problems involving risks to subjects or others [see 45 CFR 46.103(b)(5) and 21 
CFR 56.108(b)]. Refer to the IRB Policy and Procedure Manual regarding the reporting 
62 
requirements for unanticipated problems which include, but are not limited to, adverse events.  If 
you have any questions about this process, please contact the Adverse Events Coordinator at 
412-383-1480.  
The protocol and consent forms, along with a brief progress report must be resubmitted at 
least one month prior to the renewal date noted above as required by FWA00006790 (University 
of Pittsburgh), FWA00006735 (University of Pittsburgh Medical Center), FWA00000600 
(Children’s Hospital of Pittsburgh), FWA00003567 (Magee-Womens Health Corporation), 
FWA00003338 (University of Pittsburgh Medical Center Cancer Institute).  
Please be advised that your research study may be audited periodically by the University of 
Pittsburgh Research Conduct and Compliance Office.  
https://www.osiris.pitt.edu/osiris/Doc/0/GHC2S2JQEUC4521C20H2G4M3D9/fromString.... 
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APPENDIX B: CONSENT FORM 
CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY 
TITLE:  Cross-sectional Study on Postmastectomy Pain Genetics and Prognostic Value 
of Therapeutic Procedures  
PRINCIPAL INVESTIGATOR: Inna Belfer, M.D., Ph.D. 
Associate Professor of 
Anesthesiology 
University of Pittsburgh 
3550 Terrace Street 
Pittsburgh, PA 15261 
Telephone: 412-648-1342 
CO-INVESTIGATORS: 
Adam Brufsky, M.D., PhD. 
Director, Comprehensive Breast Cancer 
Center 
Associate Professor of Medicine 
University of Pittsburgh School 
of       Medicine 
Division of Hematology/Oncology 
5150 Centre Ave 
Pittsburgh, PA 
Carol M. Greco, Ph.D. 
Assistant Professor of Psychiatry 
Licensed Psychologist 
UPMC Center for Integrative 
Medicine 
580 s. Aiken Avenue, suite 310 
Pittsburgh, PA  15232 
Phone: 412-623-6873 
Fax: 412-623-6414 
Jodi Martin, BS 
Clinical Research Coordinator 
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Department of Anesthesiology 
Magee-Women's Hospital 
300 Halket St, Room 3402 
Pittsburgh, PA 15213 
Phone: 412-641-2179 
SOURCE OF SUPPORT: Department of Anesthesiology 
Why is this research being done? 
We are interested in learning why many patients who have undergone treatment for 
breast cancer (breast surgery followed by adjuvant therapy) develop Post Mastectomy Pain 
Syndrome (PMPS).  We know that surgery and associated therapies cause tissue and nerve 
damage producing inflammation and other changes, so it is not surprising that breast cancer 
patients have pain.  However, pain sometimes continues when the inflammation has calmed 
down and there is no obvious reason for continued pain.  For this reason we will examine 
whether the type and sequence of treatments for breast cancer are associated with the severity 
and duration of PMPS. We will also examine if mastectomy has changed the way body processes 
information about painful stimulation or whether concerns and anxiety about bodily functions 
and pain make patients more likely to develop PMPS. To help us understand the complex 
relationship between breast cancer-related therapy, psychological factors, response to pain 
stimulation and PMPS, we would like to measure individual responses to several harmless, but 
uncomfortable stimuli that test pain thresholds. In the end, we hope to more effectively treat the 
many patients who suffer from chronic post mastectomy pain, and predict/prevent PMPS 
development and chronicity. 
Who is being asked to take part in this research study? 
You are being invited to take part in this research study because you participated in the 
Magee Breast Cancer Registry and Banking Study, and agreed to complete the telephone 
interview.  We asked over 1300 women who were treated for breast cancer at the Magee 
Women’s Hospital to complete the telephone interview, and at that time, you agreed to 
participate in follow-up visits of pain assessment and DNA collection.  We will ask at least 200 
women to participate in this portion of our research.    
What procedures will be performed for research purposes? 
If you qualify to take part in this research study, you will undergo the experimental 
procedures listed below, including DNA collection (saliva, frozen tissue or blood sample). 
These procedures will take place at the Anesthesia Research unit located at Magee Women's 
Hospital.  The procedures will take approximately 1.5 hours to complete.   
TEST PROCEDURES: 
Testing threshold for superficial pain with small plastic filaments over hand and breast (2 
min) 
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Testing pain threshold for pressure pain with a small plate (size of a fingertip) over 
forearm and shoulder (2 min) 
Testing heat pain by briefly warming a small plate up to 47o C over hand (10 min). 
Testing cold pain by placing your hand in ice-cold water for up to 200 seconds (5 min). 
Testing ‘ischemic’ pain caused by exercise during brief stop of blood flow to the arm for 
up to 200 seconds (5 min).  
Testing smell sensitivity using standard smell identification kit (Sensonic, Inc.) 
Collecting one DNA specimen in the form of saliva in Oragene Kit, previously donated 
frozen tissue or blood depending on availability. 
Testing autonomic function (blood pressure and heart rate) 
You will be asked to answer questions regarding your mood, sleep, quality of life and 
functioning. You will be asked to answer these questions using laptop-based scales during your 
visit. 
We will record information about your breast cancer and any related treatment by 
reviewing your medical chart associated with your Registry entry.  We will not use your name, 
date of birth or medical record number to identify you, and we do not anticipate that this 
information can be used by others in a way that could affect you 
DNA GENOTYPING 
For the genetic part of this study, we are going to use DNA samples extracted from 
frozen blood samples you kindly donated previously. However, if, for any reason, blood is not 
available for DNA extraction, we are going to ask you to donate a saliva sample using a standard 
Oragene saliva kit. After your DNA will be extracted from your saliva sample, it will be 
genotyped for genetic markers (e.g., DNA sequences with a known location on a chromosome 
and associated with a particular gene or trait. We genotype single nucleotide polymorphisms – 
particular variation, which may arise due to mutation or alteration in the genomic loci, that can 
be observed in some people) in genes known to be related to human pain. The remaining DNA 
will be stored for future research involving painful disorders. Length of storage is indefinite. 
Your biologic samples will be under the control of the principal investigator of this research 
project. To protect your confidentiality, all personal identifiers (i.e., name, social security 
number, and birth date) will be removed (de-identified) and replaced with a specific code 
number. The information linking these code numbers to the corresponding subjects’ identities 
will be kept in a separate, secure location. Your biologic de-identified samples may be given to 
investigators outside of UPMC to be utilized in future studies of human pain. 
What are the possible risks, side effects, and discomforts of this research study? 
There is a potential risk of an accidental or inadvertent breach of confidentiality. We have 
taken steps to guard against this risk.   The information recorded for this research will not be 
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identified with your name or any other information that could identify you.  All information 
obtained will be identified with a code number.   
As we are interesting in understanding why people experience pain, the study will include 
several tests to determine pain thresholds.  All of these tests are often performed and do not 
cause harm or lasting pain.  However, you will at least briefly experience discomfort, at which 
point each of the tests is ended.  Any discomfort or pain will resolve completely within less than 
5 minutes.   
As part of the examinations, we will test the effect of heat.  To eliminate the chance of 
localized burns, we will stop raising the temperature, once we reached to 47o C.  The maximal 
exposure time to this temperature is limited to 3 seconds.  While you may experience pain, the 
pain should not be intense and the heat should not cause any tissue damage, as we will avoid 
conditions that can cause even minor burns.  The exposure to cold water will cause pain, which 
may be followed by tingling or a burning sensation that can last for about 1 min.  Your hand may 
become visibly red as it warms up after the cold exposure. We will ask you to exercise at keep a 
blood pressure cuff inflated to a high pressure (220 mmHg).  This pressure will exceed your own 
blood pressure.  Therefore, blood will briefly not reach your arm.  The pressure of the cuff and 
briefly blocked blood flow can cause a tingling sensation and will induce pain.  However, these 
feelings will disappear within 1 min after we remove the blood pressure cuff.  Similar to the cold 
exposure, your hand may become red after blood flow to your arm is allowed again. 
What are possible benefits from taking part in this study? 
You will likely receive no direct benefit from taking part in this research study. However 
the data obtained from this research will help to identify the genetic determinants of PMPS and 
human pain in general that will lead to better understanding of pain mechanisms and 
personalized pain medicine. 
Will my insurance provider or I be charged for the costs of any procedures performed as 
part of this research study? 
Neither you, nor your insurance provider, will be charged for the costs of any of the 
procedures performed for the purpose of this research study.  You will be charged, in the 
standard manner, for your routine medical care (e.g., regular visits to your doctor for which you 
were already scheduled).     
Will I be paid if I take part in this research study? 
You will receive a payment of $50 to reimburse you for time and effort if you complete 
the study.   
Who will pay if I am injured as a result of taking part in this study? 
If you believe that the research procedures have resulted in an injury to you, immediately 
contact the Principal Investigator who is listed on the first page of this form.  Emergency medical 
treatment for injuries solely and directly related to your participation in this research study will 
be provided to you by the hospitals of UPMC.  Your insurance provider may be billed for the 
costs of this emergency treatment, but none of those costs will be charged directly to you.  If 
your research-related injury requires medical care beyond this emergency treatment, you will be 
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responsible for the costs of this follow-up care.  At this time, there is no plan for any additional 
financial compensation. 
 
Who will know about my participation in this research study? 
Any information about you obtained from this research will be kept as confidential 
(private) as possible.  All records related to your involvement in this research study will be 
stored in a locked file cabinet.  Your identity on these records will be indicated by a case number 
rather than by your name, and the information linking these case numbers with your identity will 
be kept separate from the research records.  You will not be identified by name in any 
publication of the research results unless you sign a separate consent form giving your 
permission (release). 
 
Will this research study involve the use or disclosure of my identifiable medical 
information? 
This research study will involve the recording of current identifiable medical information 
from your medical records. The information that will be recorded will be limited to information 
concerning post mastectomy painful sensations (the duration, nature, severity and treatment of 
PMPS if you have it) and information about other diseases associated with pain (sleep or mood 
disorders).  This research study will not result in identifiable information that will be placed into 
your medical records held at UPMC Magee Women's Hospital.  
 
Who will have access to identifiable information related to my participation in this 
research study? 
If you have a high score on the depression and/or related scale, your information may be 
released to a clinical psychologist who is a co-investigator on this study; and you will be 
provided with a referral sheet to take home. 
In addition to the investigators listed on the first page of this authorization (consent) form 
and their research staff, the following individuals will or may have access to identifiable 
information (which may include your identifiable medical information) related to your 
participation in this research study:  
 
Authorized representatives of the University of Pittsburgh Research Conduct and 
Compliance Office may review your identifiable research information (which may include your 
identifiable medical information) for the purpose of monitoring the appropriate conduct of this 
research study.  
 
In unusual cases, the investigators may be required to release identifiable information 
(which may include your identifiable medical information) related to your participation in this 
research study in response to an order from a court of law.  If the investigators learn that you or 
someone with whom you are involved is in serious danger or potential harm, they will need to 
inform the related authorities, as required by Pennsylvania law. 
 
For how long will the investigators be permitted to use and disclose identifiable 
information related to my participation in this research study? 
The investigators may continue to use and disclose, for the purposes described above, 
identifiable information (which may include your identifiable medical information) related to 
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your participation in this research study for a minimum of 5 years after final reporting or 
publication of a project.  
Is my participation in this research study voluntary? 
Your participation in this research study, to include the use and disclosure of your 
identifiable information for the purposes described above, is completely voluntary.  (Note, 
however, that if you do not provide your consent for the use and disclosure of your identifiable 
information for the purposes described above, you will not be allowed to participate in the 
research study).  Whether or not you provide your consent for participation in this research study 
will have no effect on your current or future relationship with the University of Pittsburgh. 
Whether or not you provide your consent for participation in this research study will have no 
effect on your current or future medical care at a UPMC hospital or affiliated health care 
provider or your current or future relationship with a health care insurance provider. 
Your doctor is involved as an investigator in this research study.  As both your doctor and 
a research investigator, s/he is interested both in your medical care and the conduct of this 
research study.  Before agreeing to participate in this research study, or at any time during your 
study participation, you may discuss your care with another doctor who is not associated with 
this research study.  You are not under any obligation to participate in any research study offered 
by your doctor. 
May I withdraw, at a future date, my consent for participation in this research study? 
You may withdraw, at any time, your consent for participation in this research study, to 
include the use and disclosure of your identifiable information for the purposes described above. 
(Note, however, that if you withdraw your consent for the use and disclosure of your identifiable 
medical record information for the purposes described above, you will also be withdrawn, in 
general, from further participation in this research study.)  Any identifiable research or medical 
information recorded for, or resulting from, your participation in this research study prior to the 
date that you formally withdrew your consent may continue to be used and disclosed by the 
investigators for the purposes described above. 
To formally withdraw your consent for participation in this research study you should 
provide a written and dated notice of this decision to the principal investigator of this research 
study at the address listed on the first page of this form.   Your decision to withdraw your 
consent for participation in this research study will have no effect on your current or future 
relationship with the University of Pittsburgh.  Your decision to withdraw your consent for 
participation in this research study will have no effect on your current or future medical care at a 
UPMC Health System hospital or affiliated health care provider or your current or future 
relationship with a health care insurance provider. 
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 It is possible that you may be removed from the research study by the researchers if, for 
example, if your self-described symptoms do not meet inclusion criteria for the study.  If you are 
withdrawn from participation in this research study, you will continue to undergo testing and 
receive treatment as recommended by your physician. 
 If I agree to take in this research study, can I be removed from the study without my 
consent?
VOLUNTARY CONSENT 
 
All of the above has been explained to me and all of my current questions have been 
answered.  I understand that I am encouraged to ask questions about any aspect of this research 
study during the course of this study, and that such future questions will be answered by the 
researchers listed on the first page of this form.  Any questions which I have about my rights as a 
research participant will be answered by the Human Subject Protection Advocate of the IRB 
Office, University of Pittsburgh (1-866-212-2668).  
 
By signing this form, I agree to participate in this research study.  A copy of this consent 
form will be given to me. 
 
 
________________________________   __________________ 
Participant’s Signature     Date 
 
 
 
CERTIFICATION of INFORMED CONSENT 
 
I certify that I have explained the nature and purpose of this research study to the above-
named individual(s), and I have discussed the potential benefits and possible risks of study 
participation.  Any questions the individual(s) have about this study have been answered, and we 
will always be available to address future questions as they arise.”  
 
 
___________________________________  ________________________ 
Printed Name of Person Obtaining Consent  Role in Research Study 
 
 
 
_________________________________  ____________ 
Signature of Person Obtaining Consent  Date  
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APPENDIX C: STUDY SURVEY 
 
Post-Mastectomy Pain and Genetics Questionnaire 
  
1. Demographic Information 
1. Today's date 
 
3. What is your race? 
     �White or Caucasian 
�Black or African  �Asian (3) �Pacific Islander (4) �American Indian (5) 
(1)  American (2)  
Other (please specify)  
 
4. Are you Hispanic? 
   �Yes (1) �No (0) 
5. What was race/ethnicity of your father? 
     �White or Caucasian 
�Black/African  �Asian (3) �Pacific Islander (4) �American Indian (5) 
(1)  American (2)  
Other (please specify)  
 
6. What was race/ethnicity of your mother? 
       �White or Caucasian �Black or African 
 �Asian �Pacific Islander �American Indian 
American  
2 . What is your age? (years ) 
  
M
 
D
 
YYY
 Today's 
 
/ / 
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Other (please specify)  
 
7. Is your natural hair color red? 
   �Yes �No 
8. Are you right or left hand dominant? 
    
�Right �Left �Ambidextrous (eat with my �Ambidextrous (eat with my  
Right Hand)  Left Hand)  
Post-Mastectomy Pain and Genetics Questionnaire 
9. Please indicate your height and weight. Enter numeric value only. (Use 999 code to 
denote N/A status) 
Height (ex. 5'6) 
Weight (lbs) 
10. What is your marital status? 
       �Never  �Married �Separated 
�Divorced �Divorced and �Widowed �Remarried  
married  remarried  after death of  
spouse  
11. How many children do you have? 
          
�0 �1 �2 �3 �4 or more 
Post-Mastectomy Pain and Genetics Questionnaire 
  
2.  
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Dis c 
 
Post-Mastectomy Pain and Genetics Questionnaire 
  
3.  
1. Did you breastfeed your child(ren)? 
   �Yes (all children) �No, used formula (all children)
 �Some were breastfed, some were fed  
with formula  
2. What is the highest degree you have obtained? (check highest degree) 
�Never graduated �High school diploma �Trade school degree 
�College/university �Advanced degree from high school (less (12 years) beyond high school 
(12­ degree (16 years) (16­23 years) than 12 years)  14 years)  
3. Which statement best describes your current work status? 
�Working �Working �Working �Working �Retired �Retired, 
�Housekeeper, �Disabled:  
full­time, part­time, full­time, part­time, because of but not homemaker unable to work unable t OUTSIDE the 
OUTSIDE the Inside the Inside the chronic because of because of because home home home home disease chronic 
chronic disease other rea 
disease  than a  
disease Other (please specify)  
 
4. Which answer best describes how often you exercise? 
 �I never exercise �I exercise less �I exercise 1 or 2 �I 
exercise 3 or 4 �I exercise nearly �I exercise every  
than once per week  times per week  times per week  every day  day  
5. Do you currently smoke? 
    
�Yes �No 
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4.  
1. If yes, how many cigarettes per day? (20 cigarettes = 1 pack) 
  
2. If No, have you ever smoked? 
    
�Yes �No 
Post-Mastectomy Pain and Genetics Questionnaire 
  
5. 6 
1. What type of breast surgery did you undergo? 
 �Biopsy only �Breast surgery (mastectomy, �Breast surgery 
(mastectomy, �Breast surgery with Biopsy  
lumpectomy) with lymph nodes  lumpectomy) without lymph  Only  
removal  nodes removal  
 
�Other (please 
specify) 
  
Post-Mastectomy Pain and Genetics Questionnaire 
  
6.  
1. On which side was the surgery performed? 
       �Left Only �Right Only �Bilateral (one 
 �Left, then Right �Right, then Left 
surgery)  
2. Record date of breast surgery listed above (mm/yyyy). 
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3. On which side was the surgery performed? 
       �Left Only �Right Only �Bilateral (one 
 �Left, then Right �Right, then Left 
surgery)  
4. Date(s) of breast surgeries (MM/YEAR Format) FOR MULTIPLE ENTRIES, USE ";" 
  
5. What type(s) of therapies did you complete/in process of completing? Check all that 
apply. 
     �Chemotherapy �Radiation
 �Hormone (Femara,  �None 
Arimidex, Tamoxifen, Aromasin)  
Post-Mastectomy Pain and Genetics Questionnaire 
  
7.  
1. Which of these therapies were completed pre-op or post-op?  
Pre­operative Post­operative Both pre/post­op None 
Chemotherapy      
Radiation      
Hormone      
2. Did you have a reconstructive surgery? 
      
�Yes �No �Planning on one in the future 
Post-Mastectomy Pain and Genetics Questionnaire 
  
8.  
1. What type of reconstructive procedure did you have? 
   �Implant (saline, silicone) �Tissue Flap (TRAM, 
Latissimus Dorsi) �Flap(TRAM, DIEP, etc.) + Implant  
(Saline, Silicone)  
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9.  
1. Have you suffered from pain in the breast area since the reconstructive surgery? 
    
�Yes �No 
Post-Mastectomy Pain and Genetics Questionnaire 
  
10. Pain before breast surgery 
1. Did you suffer from pain before surgery (breast surgery area only)? 
    
�Yes �No 
Post-Mastectomy Pain and Genetics Questionnaire 
  
11.  
1. Please describe pain that you experienced before the breast surgery. 
None (0) Mild (1) Moderate (2) Severe (3) 
Throbbing         
Shooting         
Stabbing         
Sharp         
Cramping         
Gnawing         
Hot­Burning         
Aching         
Heavy         
Tender         
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Splitting         
Tiring­Exhausting         
Sickening         
Fearful         
Punishing­Cruel         
2. Please rate the intensity of pain before the breast surgery. 
                 �0­no �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
pain  worst  
possible 
pain  
3. What was the location of your pain before the breast surgery? 
     �Entire Breast �Nipple Region �No 
Specific Location 
 
�Other (please 
specify) 
  
Post-Mastectomy Pain and Genetics Questionnaire 
  
12. Brief Pain Inventory (BPI) 
Throughout our lives, most of us have had pain from time to time (such as toothache, minor headaches, sprains). Please rate 
your pain OTHER than everyday kind of pain on a "0" to "10" scale in the last week.  
1. What is your pain level at the PRESENT time, that is, right now? 
                 �0­no �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
pain  pain as  
bad as 
could be  
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13.  
1. During the PAST week, ON AVERAGE, how INTENSE was your pain? 
                 �0­no �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
pain  pain as  
bad as 
could 
be  
14.  
1. During the PAST week, what was the LOWEST level of your pain? 
                 �0­no �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
pain  pain as  
bad as 
could 
be  
15.  
1. During the PAST week, how INTENSE was your WORST pain? 
                 �0­no �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
pain  pain as  
bad as 
could 
be  
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16. Brief Pain Inventory (BPI) 
For the next ten questions, check the one number that describes how, during the PAST WEEK, PAIN has interfered with your:  
1. General Activity 
                 �0­ �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
does not  completely interfere  interferes  
2. Mood 
                 �0­ �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
does not  completely interfere  interferes  
3. Walking Ability 
                 �0­ �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
does not  completely interfere  interferes  
4. Normal Work (includes both work outside the home and housework) 
                 �0­ �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
does not  completely interfere  interferes  
5. Relations with other people 
                 �0­ �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
does not  completely interfere  interferes  
6. Sleep 
                 �0­ �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
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 does not  completely interfere  interferes  
7. Enjoyment of Life 
                 �0­ �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
does not  completely interfere  interferes  
Post-Mastectomy Pain and Genetics Questionnaire 
8. Recreational activities 
                 �0­ �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
does not  completely interfere  interferes  
9. Self-care (eating, dressing, etc.) 
                 �0­ �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
does not  completely interfere  interferes  
10. Social activities 
                 �0­ �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
does not  completely interfere  interferes  
Post-Mastectomy Pain and Genetics Questionnaire 
  
17. Phantom Breast Pain 
1. Have you experienced PHANTOM BREAST PAIN since the surgery(i.e pain in the breast 
that has been removed)? 
      
�Yes �No �Not Applicable (Biopsy only) 
Post-Mastectomy Pain and Genetics Questionnaire 
  
18.  
1. When did you first notice post-surgery phantom breast pain (i.e. pain in the breast that 
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 has been removed)? 
�Within a week after �Within one month �Within first 3 months �Three to 12 
months �Over a year after breast surgery after breast surgery after breast surgery after breast surgery 
breast surgery  
2. Are you CURRENTLY experiencing phantom breast pain? 
    
�Yes �No 
Post-Mastectomy Pain and Genetics Questionnaire 
  
19.  
1. Please describe the type of pain that you experience now. 
None (0) Mild (1) Moderate (2) Severe (3) 
Throbbing        
Shooting        
Stabbing        
Sharp        
Cramping        
Gnawing        
Hot/Burning        
Aching        
Heavy        
Tender        
Splitting        
Exhausting        
Sickening        
Fearful        
Punishing/Cruel        
2. If No, how long did the pain last? 
       �0­3 months �3­6 months �6­12 
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 months �over 12 months 
3. Rate the average intensity of phantom breast pain that you PRESENTLY have OR 
PREVIOUSLY experienced on the 0-10 scale. "0" is "no pain" and "10" is "worst possible 
pain. 
                 �0­no �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
pain  worst  
possible 
pain  
4. How long do/did individual episodes of phantom breast pain USUALLY last? 
       �Few seconds �Few minutes �Longer 
than few minutes �Constant Pain 
5. How often do/did you USUALLY experience episodes of phantom breast pain? 
       �Every day �Every week �Every month
 �Less than once a month 
Post-Mastectomy Pain and Genetics Questionnaire 
6. What are some factors that affect(ed) your phantom breast pain (i.e. pain in the breast 
that has been removed)? 
Yes No 
Menstruation   
Change in weather   
Time of the day   
Sexual arousal   
Touch or pressure   
Psychological Stress   
Physical Stress   
Other (please specify)  
 
Post-Mastectomy Pain and Genetics Questionnaire 
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 20. Pain Assessment 
We are interested to learn about the pain, if any, that you may be experiencing in the area you had surgery. We are also 
interested in pain on the operated side in your chest, armpit or arm.  
  
By pain we mean that an area of your body is the cause of discomfort or hurts. We are interested in all pain, from a light 
discomfort to severe pain.  
1. Within the LAST 3 MONTHS, have you experienced pain the area of the breast, armpit, 
arm, or chest on the operated side(s)? Please account for ongoing pain as well as pain 
evoked by activity. 
    
�Yes �No 
Post-Mastectomy Pain and Genetics Questionnaire 
  
21.  
1. Type of pain in the past 3 months 
      
�Random �Ongoing �Evoked (activity, etc.) 
Post-Mastectomy Pain and Genetics Questionnaire 
  
22.  
1. Please select area(s) where you experienced pain in the last 3 months (since the breast 
surgery) 
          
�Breast �Arm �Armpit �Side of the  �Upper Back
 �Neck 
body/Chest  
Post-Mastectomy Pain and Genetics Questionnaire 
  
23.  
1. Please select where in the BREAST area you experience pain. 
        
�RUQ �RLQ �LUQ �LLQ �Above  �Below 
 �Side of the  
Nipple  Nipple  Nipple  
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 2. When you experience pain in/around breast, please indicate AVERAGE SEVERITY of 
pain in the last 3 months. 
                 �0­no �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
pain  severe  
pain  
3. When you experience pain in/around the breast, how often does this occur? 
          
�Constant �Daily �Weekly �Monthly �Seasonal 
4. For each pain description, please select AVERAGE INTENSITY of breast pain in the 
past 3 months.  
None (0) Mild (1) Moderate (2) Severe (3) 
Throbbing     
Shooting     
Stabbing     
Sharp     
Cramping     
Gnawing     
Hot­Burning     
Aching     
Heavy     
Tender     
Splitting     
Tiring­Exhausting     
Sickening     
Fearful     
Punishing­Cruel     
5. Rank Overall Pain Intensity (PPI) in/around area of the breast based on pain 
description(s) above. 
         �No Pain (0) �Mild (1)
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  �Discomforting �Distressing (3) �Horrible (4) �Excruciating (5) 
(2)  
Post-Mastectomy Pain and Genetics Questionnaire 
6. When you experience pain in/around SIDE OF THE CHEST, please indicate AVERAGE 
SEVERITY of pain in the last 3 months. 
                 �0­no �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
pain  most  
severe  
7. When you experience pain in/around side of the chest, how often does this occur? 
          
�Constant �Daily �Weekly �Monthly �Seasonal 
8. For each pain description, please select AVERAGE INTENSITY of pain on the side of 
the chest in the past 3 months. 
None (0) Mild (1) Moderate (2) Severe (3) 
Throbbing     
Shooting     
Stabbing     
Sharp     
Cramping     
Gnawing     
Hot­Burning     
Aching     
Heavy     
Tender     
Splitting     
Tiring­Exhausting     
Sickening     
Fearful     
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 Punishing­Cruel     
9. Rank overall pain intensity (PPI) in/around the side of the chest based on pain 
description(s) above. 
         �No Pain (0) �Mild (1)
 �Discomforting �Distressing (3) �Horrible (4) �Excruciating (5) 
(2)  
10. When you experience pain in/around ARMPIT, please indicate AVERAGE SEVERITY of 
pain in the last 3 months. 
                 �0­no �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
pain  most  
severe  
Post-Mastectomy Pain and Genetics Questionnaire 
11. When you experience pain in/around the armpit, how often does this occur? 
          
�Constant �Daily �Weekly �Monthly �Seasonal 
12. For each pain description, please select AVERAGE INTENSITY of armpit pain in the 
past 3 months. 
None (0) Mild (1) Moderate (2) Severe (3) 
Throbbing     
Shooting     
Stabbing     
Sharp     
Cramping     
Gnawing     
Hot­Burning     
Aching     
Heavy     
Tender     
Splitting     
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 Tiring­Exhausting     
Sickening     
Fearful     
Punishing­Cruel     
13. Rank overall pain intensity (PPI) in/around the armpit based on pain description(s) 
above. 
         �No Pain (0) �Mild (1)
 �Discomforting �Distressing (3) �Horrible (4) �Excruciating (5) 
(2)  
14. When you experience pain in the ARM, please indicate AVERAGE SEVERITY of pain in 
the last 3 months. 
                 �0­no �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
pain  most  
severe  
15. When you experience pain in the arm, how often does this occur? 
          
�Constant �Daily �Weekly �Monthly �Seasonal 
Post-Mastectomy Pain and Genetics Questionnaire 
16. For each pain description, please select AVERAGE INTENSITY of arm pain in the past 
3 months. 
None (0) Mild (1) Moderate (2) Severe (3) 
Throbbing     
Shooting     
Stabbing     
Sharp     
Cramping     
Gnawing     
Hot­Burning     
Aching     
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 Heavy     
Tender     
Splitting     
Tiring­Exhausting     
Sickening     
Fearful     
Punishing­Cruel     
17. Rank overall pain intensity (PPI) in the arm based on pain description(s) above. 
         �No Pain (0) �Mild (1)
 �Discomforting �Distressing (3) �Horrible (4) �Excruciating (5) 
(2)  
Post-Mastectomy Pain and Genetics Questionnaire 
  
24. Pain Medication 
1. Do you take painkillers (Tylenol, Vicodin, Fentanyl) for pain in the area of breast surgery 
(breast, armpit, arm, chest)? 
    
�Yes �No 
Post-Mastectomy Pain and Genetics Questionnaire 
  
25.  
1. Please select the most appropriate choice(s) for pain relief 
�Over the counter meds (ibuprofen,  �Opioids (morphine, oxycodone,  �Special pain 
meds (gabapentin, lyrica,  
tylenol, aspirin)  codeine)  lamictal, tramadol, etc.)  
 
�Other (please 
specify) 
  
2. How effective are painkillers in relieving your breast surgery pain?  
                 �0­not �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
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 at all  complete  
pain relief  
3. How often do you take painkillers? 
   �Constantly (more �Daily 
(part of routine �Weekly �Monthly �Occasionally  
than suggested daily  meds regimen)  (seasonal/few times dose)  throughout the year)  
4. Please list pain medication dose below. (FORMAT: mg x daily frequency)  
  
Advil/Ibuprofen 200 mg  
Tylenol/Acetaminophen Regular -325 mg, Extra Strength -500 mg  
Aspirin Regular -325 mg, Extra Strength -500 mg  
 
Post-Mastectomy Pain and Genetics Questionnaire 
  
26. Pain in other places in the body. 
We are interested to learn about the pain, if any, you are experiencing in places other than breast surgery.  
1. We are interested to learn about the pain, if any, you are experiencing in other places 
than where you were operated. This pain does not have to be related to your breast 
surgery. Do you experience pain in any other area of the body than the area where you 
had surgery?  
    
�Yes �No 
Post-Mastectomy Pain and Genetics Questionnaire 
  
27.  
1. Has the pain begun before/after therapy(ies)? 
   �Before �After �Currently completing �Pain was present 
�I did not complete  
therapy/ only present throughout (before and any therapies during 
therapy after)  
Post-Mastectomy Pain and Genetics Questionnaire 
 
 
 
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28.  
1. Did you ever notice pain in any other area of the body following breast surgery? Area(s) 
other than the site of breast surgery. 
    
�Yes �No 
Post-Mastectomy Pain and Genetics Questionnaire 
  
29.  
1. Did the pain begin before or after therapy(ies)? 
   �Before �After �Currently completing �Pain has been 
there �I did not have to  
therapies/ pain was only  throughout (before and  complete any follow­up  
present during therapies  after)  therapies  
Post-Mastectomy Pain and Genetics Questionnaire 
  
30.  
1. Have you had a pre-existing chronic pain condition (prior to breast surgery)? 
    
�Yes �No 
Post-Mastectomy Pain and Genetics Questionnaire 
  
31.  
1. Yes, please select pain problem(s) area(s)  
         �Head/  �Neck/Shoulders 
�Low back/ �Knees �Ankles �Abdomen �Hands/Wrists 
Sinuses  Hips  
 
�Other (please 
specify) 
  
2. On the scale 0-10, please indicate the severity of pain in the area(s) that gives you the 
most trouble.  
                 �0­no �1 
�2 �3 �4 �5 �6 �7 �8 �9 
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 �10­ 
pain  severe  
pain  
3. How often do you experience pain in the located area(s). Indicate frequency of pain 
occurrence in the area that gives you the most trouble. 
         �Constantly �Daily �Weekly
 �Monthly �Seasonal 
4. For each pain description, please indicate AVERAGE SEVERITY of pain in the area that 
gives you the most trouble. 
None (0) Mild (1) Moderate (2) Severe (3) 
Throbbing     
Shooting     
Stabbing     
Sharp     
Cramping     
Gnawing     
Hot­Burning     
Aching     
Heavy     
Tender     
Splitting     
Tiring­Exhausting     
Sickening     
Fearful     
Punishing­Cruel     
 
Post-Mastectomy Pain and Genetics Questionnaire 
5. Please indicate overall pain intensity in the area that gives you most trouble. 
         �No Pain (0) �Mild (1)
 �Discomforting �Distressing (3) �Horrible (4) �Excruciating (5) 
(2)  
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32. Sensory disturbances 
We would like to learn if you are experiencing sensory disturbances such as pins and needles or prickling sensations in the area 
of your breast surgery. WITHIN THE PAST 3 MONTHS, HAVE YOU...  
1. ...had pins and needles, shooting or stabbing sensations in or around the area of your 
surgery? 
   �Yes �No 
2. ...experienced an electric shock like sensation or jabbing feelings in the skin area in or 
around the area of your surgery? 
   �Yes �No 
3. ...experienced hot or burning sensations in or around the area of breast surgery?  
   �Yes �No 
4. ...had numbness or decreased sensitivity in or around the area of your surgery? 
   �Yes �No 
5. ...had the lightest of touches cause pain in or around the area of breast surgery? (e.g.  
clothes) 
   �Yes �No 
6. ...cold temperatures been the cause of pain in or around the area of breast surgery? 
   �Yes �No 
7. ...experienced a painful itch in or around the area of your surgery? 
   �Yes �No 
8. If you have experienced any of the sensory disturbances, where have they originated 
from? Please check all that apply.  
          
�Breast �Armpit �Arm �Side of the chest �None 
 
�Other (please 
specify) 
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Post-Mastectomy Pain and Genetics Questionnaire 
  
33. Lymphedema Assessment 
1. Within the PAST 3 MONTHS, have you experienced swelling, tensions or heaviness in 
the breast, armpit, arm, or back of your hand on the side of breast surgery? 
    
�Yes �No 
Post-Mastectomy Pain and Genetics Questionnaire 
  
34.  
1. If yes, I have a SENSATION of heaviness, swelling, or tension in... 
          
�N/A �Breast �Armpit �Arm �Side of chest 
�Back of the  
hand  
2. Please indicate how severe the sensation has been 
                 �0­not �1 
�2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
at all  very  
severe  
3. If there is a VISIBLE DIFFERENCE between the operated and non-operated sides, the 
operated side is noticeably bigger. Please indicate location of the swelling. 
          
�N/A �Breast �Armpit �Arm �Side of chest 
�Back of the  
hand  
Post-Mastectomy Pain and Genetics Questionnaire 
  
35.  
1. Please indicate how visible the difference is between the operated and non-operated 
sides.  
                 �0­not �1 
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 �2 �3 �4 �5 �6 �7 �8 �9 
�10­ 
at all  very  
severe  
2. Have you undergone treatment for lymphedema? 
  
�No �Yes, lymphatic drainage by �Yes, arm and wrist  �Yes, 
physical therapy  
a physical therapist  bandages  exercises  
 
�Other (please 
specify) 
  
Post-Mastectomy Pain and Genetics Questionnaire 
  
36. Daily Activities 
We are interested to learn how breast surgery has affected your daily activities. During the PAST 3 MONTHS how were the 
following activities affected...  
1. Carrying and/or lifting (grocery bags, luggage, children) 
   �Not relevant, I don't do this �I can do this without any 
�I can do this, but with  �I can't do this  
problem  difficulties  
Post-Mastectomy Pain and Genetics Questionnaire 
  
37.  
1. Is the cause of your limitation(s) due to ongoing/evoked pain in (or around) the area of 
the breast surgery? 
     �Ongoing �Evoked (pressure,  �N/A
 �Ongoing and evoked 
exercise,etc.)  
2. Reaching and/or raising your arms above your head 
   �Not relevant, I don't do this �I can do this without any 
�I can do this but difficulties �I can't do this  
problem  because  
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38.  
1. Is the cause of your limitation(s) due to ongoing/evoked pain in (or around) the area of 
the breast surgery? 
        
�Ongoing �Evoked �N/A �Ongoing and evoked 
2. Pushing a heavy door 
   �Not relevant, I don't do this �I can do this without any 
�I can do this, but with  �I can't do this 
problem  difficulties because  
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39. 
1. Is the cause of your limitation(s) due to ongoing/evoked pain in (or around) the area of
the breast surgery? 
�Ongoing �Evoked �N/A �Ongoing and evoked
2. Pulling a heavy door
�Not relevant, I don't do this �I can do this without any
�I can do this, but with �I can't do this
problem  difficulties because 
Post-Mastectomy Pain and Genetics Questionnaire
40. 
1. Is the cause of your limitation(s) due to ongoing/evoked pain in (or around) the area of
the breast surgery? 
�Ongoing �Evoked �N/A �Ongoing and evoked
2. Bending over
�Not relevant, I don't do this �I can do without any
�I can do this, but with �I can't do this
problem difficulties because 
41. 
1. Is the cause of your limitation(s) due to ongoing/evoked pain in (or around) the area of
the breast surgery? 
�Ongoing �Evoked �N/A �Ongoing and evoked
2. Walking
�Not relevant, I don't do this �I can do this without any
�I can do this, but with �I can't do this
problem  difficulties because 
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42. 
1. Is the cause of your limitation(s) due to ongoing/evoked pain in (or around) the area of
the breast surgery? 
�Ongoing �Evoked �N/A �Ongoing and evoked
2. Exercising/ Sports activities
�Not relevant, I don't do this �I can do this without any
�I can do this, but with �I can't do this
problem  difficulties because 
43. 
1. Is the cause of your limitation(s) due to ongoing/evoked pain in (or around) the area of
the breast surgery? 
�Ongoing �Evoked �N/A �Ongoing and evoked
2. Driving
�Not relevant, I don't do this �I can do this without any
�I can do this, but with �I can't do this
problem  difficulties because 
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44. 
1. Is the cause of your limitation(s) due to ongoing/evoked pain in (or around) the area of
the breast surgery? 
�Ongoing �Evoked �N/A �Ongoing and evoked
2. Self-Care (putting on a bra, washing hair, taking off a sweater)
�Not relevant, I don't do this �I can do this without any
�I can do this, but with �I can't do this 
problem difficulties because 
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45.  
1. Is the cause of your limitation(s) due to ongoing/evoked pain in (or around) the area of 
the breast surgery? 
        
�Ongoing �Evoked �N/A �Ongoing and evoked 
2. Having Sexual Intercourse 
   �Not relevant �I can do this without any �I can do this, 
but with  �I can't do this 
problems  limitations  
Post-Mastectomy Pain and Genetics Questionnaire 
  
46.  
1. Is the cause of your limitation(s) due to ongoing/evoked pain in (or around) the area of 
the breast surgery? 
        
�Ongoing �Evoked �N/A �Ongoing and evoked 
Post-Mastectomy Pain and Genetics Questionnaire 
  
47. Emotional Stability Form 
Below is a list a of common human traits. Select a response that best describes how you see yourself at the PRESENT time, not 
as you wish to be in the future. Describe yourself as you are generally or typically, as compared with other persons you know of 
the same sex and of roughly the same age.  
1. Anxious 
 �Not at all accurate �A little accurate (1) 
�Moderately accurate �Quite a bit accurate �Extremely accurate  
(0)  (2)  (3)  (4)  
2. Touchy (sensitive) 
 �Not at all accurate �A little accurate (1) 
�Moderately accurate �Quite a bit accurate �Extremely accurate  
(0)  (2)  (3)  (4)  
3. Nervous 
 �Not at all accurate �A little accurate (1) 
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 �Moderately accurate �Quite a bit accurate �Extremely accurate  
(0)  (2)  (3)  (4)  
4. Tense 
 �Not at all accurate �A little accurate (1) 
�Moderately accurate �Quite a bit accurate �Extremely accurate  
(0)  (2)  (3)  (4)  
5. Irritable 
 �Not at all accurate �A little accurate (1) 
�Moderately accurate �Quite a bit accurate �Extremely accurate  
(0)  (2)  (3)  (4)  
6. Sad 
 �Not at all accurate �A little accurate (1) 
�Moderately accurate �Quite a bit accurate �Extremely accurate  
(0)  (2)  (3)  (4)  
7. Happy 
 �Not at all accurate �A little accurate (1) 
�Moderately accurate �Quite a bit accurate �Extremely accurate  
(0)  (2)  (3)  (4)  
8. Resentful 
 �Not at all accurate �A little accurate (1) 
�Moderately accurate �Quite a bit accurate �Extremely accurate  
(0)  (2)  (3)  (4)  
9. Relaxed 
 �Not at all accurate �A little accurate (1) 
�Moderately accurate �Quite a bit accurate �Extremely accurate  
(0)  (2)  (3)  (4)  
Post-Mastectomy Pain and Genetics Questionnaire 
10. Depressed 
 �Not at all accurate �A little accurate (1) 
�Moderately accurate �Quite a bit accurate �Extremely accurate  
(0)  (2)  (3)  (4)  
Post-Mastectomy Pain and Genetics Questionnaire   
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48. Emotional Distress - Anxiety Short form 
  
Please respond to each item by selecting only one response. IN THE PAST 7 DAYS...  
1. I felt fearful... 
       �Never (1) �Rarely (2)
 �Sometimes (3) �Often (4) 
2. I felt anxious... 
       �Never (1) �Rarely (2)
 �Sometimes (3) �Often (4) 
3. I felt worried... 
       �Never (1) �Rarely (2)
 �Sometimes (3) �Often (4) 
4. I found it hard to focus on anything other than my anxiety... 
       �Never (1) �Rarely (2)
 �Sometimes (3) �Often (4) 
5. I felt nervous... 
       �Never (1) �Rarely (2)
 �Sometimes (3) �Often (4) 
6. I felt uneasy... 
       �Never (1) �Rarely (2)
 �Sometimes (3) �Often (4) 
7. I felt tense... 
 
 
 
 
 
 
  
Always (5) 
  
Always (5) 
  
Always (5) 
  
Always (5) 
  
Always (5) 
  
Always (5) 
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        �Never (1) �Rarely (2)
 �Sometimes (3) �Often (4) 
   
Always (5) 
Post-Mastectomy Pain and Genetics Questionnaire   
  
49. Emotional Distress - Depression Short Form 
  
102 
 1. I felt 
worthless... 
 
�Never (1)
  
2 
 
�Never (1)
  
3. I felt helpless... 
 
�Never (1)
  
4. I felt sad... 
 
�Never (1)
  
5. I felt like a 
failure... 
 
�Never (1)
  
6. I felt 
depressed... 
 
�Never (1)
  
7. I felt unhappy... 
 
�Never (1)
  
8. I felt 
hopeless... 
Please respond 
to each item by 
selecting only 
one response. 
IN THE PAST 7 
DAYS... 
 
Rarely (2) 
. I felt that I 
had 
nothing to 
look 
forward 
to... 
  
Rarely (2) 
  
Rarely (2) 
  
Rarely (2) 
  
Rarely (2) 
  
Rarely (2) 
  
Rarely (2) 
 
 
 
 
 
 
 
  
Sometimes (3) 
  
Sometimes (3) 
  
Sometimes (3) 
  
Sometimes (3) 
  
Sometimes (3) 
  
Sometimes (3) 
  
Sometimes (3) 
 
 
 
 
 
 
 
  
  
Often (4) 
  
Often (4) 
  
Often (4) 
  
Often (4) 
  
Often (4) 
  
Often (4) 
  
Often (4) 
 
 
 
 
 
 
 
  
Always (5) 
  
Always (5) 
  
Always (5) 
  
Always (5) 
  
Always (5) 
  
Always (5) 
  
Always (5) 
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        �Never (1) �Rarely (2)
 �Sometimes (3) �Often (4) 
   
Always (5) 
Post-Mastectomy Pain and Genetics Questionnaire   
  
50. Sleep Disturbance - Short Form 
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 Please respond to each item by selecting 
one response. IN THE PAST 7 DAYS... 
1. My sleep was restless... 
   
�Not at all (1) �A 
little bit (2) 
2. I had difficulty falling 
asleep... 
   
�Not at all (5) �A 
little bit (4) 
3. I had trouble staying 
asleep... 
   �Never 
(1) �Rarely (2) 
4. I had trouble sleeping... 
   �Never 
(1) �Rarely (2) 
5. I was satisfied with my 
sleep... 
   
�Not at all (5) �A 
little bit (4) 
6. My sleep was refreshing... 
   
�Not at all (5) �A 
little bit (4) 
7. I got enough sleep... 
   �Never 
(5) �Rarely (4) 
8. My sleep quality was... 
 
 
 
 
 
 
 
  
Somewhat (3) 
  
Somewhat (3) 
  
Sometimes (3) 
  
Sometimes (3) 
  
Somewhat (3) 
  
Somewhat (3) 
  
Sometimes (3) 
 
 
 
 
 
 
 
  
  
Quite a bit 
(4) 
  
Quite a bit 
(2) 
  
Often (4) 
  
Often (4) 
  
Quite a bit 
(2) 
  
Quite a bit 
(2) 
  
Often (2) 
 
 
 
 
 
 
 
  
Very much 
(5) 
  
Very much 
(1) 
  
Always (5) 
  
Always (5) 
  
Very much 
(1) 
  
Very much 
(1) 
  
Always (1) 
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        �Very poor (5)
 �Poor (4) �Fair (3) �Good (2) 
   
Very good (1) 
Post-Mastectomy Pain and Genetics Questionnaire 
  
51. Perceived Stress Scale (PSS) 
The questions in this scale ask you about your feelings and thoughts during the last month. In each case, you will be asked to 
indicate HOW OFTEN you felt or thought a certain way. Although some of the questions are similar, there are differences 
between them and you should treat each one as a separate question. The best approach is to answer fairly quickly. That is, don't 
try to count up the number of times you felt a particular way; rather indicate the alternative that seems like a reasonable 
estimate.  
  
Give the choice that best fits how you have been feeling in the PAST MONTH.  
1. ...been upset because of something that happened unexpectedly? 
         �Never (0) �Almost never (1)
 �Sometimes (2) �Fairly often (3) �Often (4) 
2. ...felt unable to control the important things in your life? 
         �Never (0) �Almost never (1)
 �Sometimes (2) �Fairly often (3) �Often (4) 
3. ...felt nervous and "stressed"? 
         �Never (0) �Almost never (1)
 �Sometimes (2) �Fairly often (3) �Often (4) 
4. ...felt confident about your ability to handle your personal problems? 
         �Never (4) �Almost never (3)
 �Sometimes (2) �Fairly often (1) �Often (0) 
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 5. ...felt that things were going your way? 
         �Never (4) �Almost never (3)
 �Sometimes (2) �Fairly often (1) �Often (0) 
6. ...found that you could not cope with all the things that you had to do? 
         �Never (0) �Almost never (1)
 �Sometimes (2) �Fairly often (3) �Often (4) 
7. ...been able to control irritations in your life? 
         �Never (4) �Almost never (3)
 �Sometimes (2) �Fairly often (1) �Often (0) 
8. ...felt that you were on top of things? 
         �Never (0) �Almost never (1)
 �Sometimes (2) �Fairly often (3) �Often (4) 
9. ...been angered because of things that happened that were outside of your control? 
         �Never (0) �Almost never (1)
 �Sometimes (2) �Fairly often (3) �Often (4) 
10. ...felt that difficulties were piling up so high that you could not overcome them? 
         �Never (0) �Almost never (1)
 �Sometimes (2) �Fairly often (3) �Often (4) 
Post-Mastectomy Pain and Genetics Questionnaire 
  
52. Concentration and Memory 
We would like to know how your memory and energy have been affected since the surgery. Please indicate how you have been 
feeling during the LAST MONTH.  
1. I have difficulty concentrating 
        
�Never �To some degree �Quite a bit �Very much 
2. I have more difficulty concentrating now than before my surgery 
        
�Never �To some degree �Quite a bit �Very much 
3. I feel that I don't have the energy to solve problems 
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 �Never �To some degree �Quite a bit �Very much 
4. I feel that I quickly get tired in my head since the surgery 
        
�Never �To some degree �Quite a bit �Very much 
Post-Mastectomy Pain and Genetics Questionnaire 
  
53. Pain Catastrophizing Scale (PCS) 
Everyone experiences painful situations at some point in their lives. Such experiences may include headaches, tooth pain, joint 
or muscle pain. People are often exposed to situations that may cause pain such as illness, injury, dental procedures, or surgery. 
WE ARE INTERESTED IN THE TYPES OF THOUGHTS AND FEELINGS THAT YOU HAVE WHEN YOU ARE IN PAIN. Listed below are 14 
statements describing different thoughts and feelings that may be associated with pain. Using the following scale, please 
indicate the degree to which you have these thoughts and feelings when you are experiencing pain.  
1. I worry all the time about whether it will end. 
   �Not at all (0) �To a slight degree �To a moderate 
 �To a great degree �All the time (4) 
(1) degree (2)  (3)  
2. I feel I cannot go on. 
   �Not at all (0) �To a slight degree �To a moderate 
 �To a great degree �All the time (4) 
(1) degree (2)  (3)  
3. It's terrible and I think it's never going to get any better. 
   �Not at all (0) �To a slight degree �To a moderate 
 �To a great degree �All the time (4) 
(1) degree (2)  (3)  
4. It's awful and I feel that it overwhelms me. 
   �Not at all (0) �To a slight degree �To a moderate 
 �To a great degree �All the time (4) 
(1) degree (2)  (3)  
5. I feel I can't stand it anymore. 
   �Not at all (0) �To a slight degree �To a moderate 
 �To a great degree �All the time (4) 
(1) degree (2)  (3)  
6. I become afraid that the pain will get worse. 
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    �Not at all (0) �To a slight degree �To a moderate 
 �To a great degree �All the time (4) 
(1) degree (2)  (3)  
7. I keep thinking of other painful events. 
   �Not at all (0) �To a slight degree �To a moderate 
 �To a great degree �All the time (4) 
(1) degree (2)  (3)  
8. I anxiously want the pain to go away. 
   �Not at all (0) �To a slight degree �To a moderate 
 �To a great degree �All the time (4) 
(1) degree (2)  (3)  
Post-Mastectomy Pain and Genetics Questionnaire   
9. I can't seem to get it out of my mind.     
 �Not at all (0) �To a slight degree �To 
a moderate  �To a great degree  
(1)  degree (2)  (3)  
10. I keep thinking about how much it hurts. 
 �Not at all (0) �To a slight degree �To 
a moderate  �To a great degree  
(1) degree (2)  (3)  
11. I keep thinking about how badly I want the pain to stop. 
 �Not at all (0) �To a slight degree �To 
a moderate  �To a great degree  
(1) degree (2)  (3)  
12. There's nothing I can do to reduce the intensity of the pain. 
 �Not at all (0) �To a slight degree �To 
a moderate  �To a great degree  
(1) degree (2)  (3)  
13. I wonder whether something serious may happen. 
 �Not at all (0) �To a slight degree �To 
a moderate  �To a great degree  
(1) degree (2)  (3)  
 
 
 
 
 
  
All the time 
(4) 
  
All the time 
(4) 
  
All the time 
(4) 
  
All the time 
(4) 
  
All the time 
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 14. I feel my life isn't worth living. (4) 
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  �Not at all (0) �To a slight degree �To 
a moderate  �To a great degree  
(1)  degree (2)  (3)  
   
All the time 
(4) 
Post-Mastectomy Pain and Genetics Questionnaire 
  
54. Follow-Up Contact 
Thank you very much for your time, Ms._________(Last Name)! I really appreciate your help with the study!  
1. May we contact you again in the future? 
    
�Yes �No 
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